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Advanced glycation endproducts: formation pathways 
Glucose and non-glucose dependent pathway    
With increasing glucose levels, various biochemical processes will change or 
will be stimulated or activated, and other endproducts will be formed than in 
normoglycemic conditions. For example, the prostaglandins and leukotrienes formed 
during hyperglycemia are different from those formed during normoglycemia. Also, 
various types of leukocytes are stimulated to form enzymes contributing to glycation. 
Still, increased glucose levels per se are eliciting only a small part of the possible 
problems and complications, associated with diseases like diabetes mellitus (DM). 
In patients with hyperglycemia, glucose will – quite often irreversibly – bind to 
other molecules inside the human body like aminoacids, and to a lesser extent fatty 
acids and nucleic acids, leading to glycation of these molecules. Glycation can be 
accompanied by oxidation, contributing to further adverse changes (see also below). 
The basic chemistry of the formation of advanced glycation endproducts (AGEs) was 
first described by the French food chemist Louis Camille Maillard in 1912. The so-
called Maillard reaction is based on a non-enzymatic reaction between amino acids 
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The starting point of the Maillard reaction is the formation of a Schiff base: an 
aldehyde group of a glucose molecule combines with an amino group of an amino 
acid molecule in a protein to form an imine or Schiff base. The next step is the 
formation of an Amadori product, an organic reaction; this re-arrangement of the 
Schiff base means the move of the hydrogen atom from the hydroxyl group adjacent 
to the carbon-nitrogen, leaving a ketone. And the last step is the oxidation of the 
Amadori products, most often by transition metal catalysis, which leads to the 
irreversible formation of AGEs. This endogenous and slow formation of AGEs is 
concentration-dependent at the early stage of the Maillard reaction and accelerates 
under circumstances of hyperglycemia (1,2).
A non-glucose-dependent AGE pathway involves the inflammatory stimulation 
of neutrophils, monocytes, and macrophages, which produce myeloperoxidase 
and NADPH oxidase enzymes which are able to form reactive carbonyls and Nε-
carboxymethyllysine (CML) by oxidizing amino acids (3). This could explain the 
production of increased AGE formation in various inflammatory diseases, such as 
systemic lupus erythematosus and rheumatoid arthritis (4-7). 
Oxidative stress  
Besides the classical Maillard reaction, oxidative stress is another pathway that 
results in AGE-formation. Oxidative stress is an imbalance between the systemic 
manifestation of reactive oxygen species (ROS) and the protective mechanisms 
against oxidative stress (see below). Mitochondrial overproduction of ROS is a 
consequence of intracellular hyperglycemia or increased oxidation of fatty acids 
and plays a central role in the formation of intracellular methylglyoxal (MGO)-
derived AGEs. Oxidation of fatty acids, resulting in part from pathway-specific insulin 
resistance, and non-oxidative mechanisms (e.g. anaerobic glycolysis) are responsible 
for the formation of dicarbonyls, which in turn bind amino acids to form AGEs. This 
so-called dicarbonyl stress pathway encompasses the rapid formation of reactive 
intermediate products such as MGO and 3-deoxyglucosone, which are also termed 
dicarbonyls, oxoaldehydes or reactive carbonyl compounds (8-10). Lipid peroxidation 
in the presence of ribonuclease A, a protein that contains neither enzymatically nor 
nonenzymatically attached carbohydrates, results directly into the formation of 






































Patients with end stage renal disease (ESRD) on hemodialysis have much higher 
AGE levels than healthy subjects because of increased levels of oxidative stress and 
reduced antioxidant levels. Furthermore, in uremia CML and pentosidine production 
is supposed to be determined both by an increased level of oxidative stress and the 
availability of precursors of these AGEs, irrespective of the presence or absence of a 
hyperglycemic state (12-14).
Exogenous sources of AGEs
Besides the above mentioned endogenous sources of AGEs, dietary intake and 
smoking are the prominent exogenous sources of AGEs. The oral bioavailability of 
AGEs absorbed from ingested food is estimated at about 10% and these diet-derived 
AGEs are similar to native AGEs with respect to the prooxidant and proinflammatory 
characteristics (15,16). Auto-oxidation of glucose is accompanied by the generation 
of superoxide radicals and ingested glycoxidation and lipoxidation products can 
accelerate free radical generation and oxidative and carbonyl stress (17). Cigarette 
smoke contains high concentrations of glyoxal and MGO due to the thermal 
decomposition of saccharides, which are the most likely mediating factors of smoking 
associated AGE formation (18). 
Removal of AGEs    
There are a few key factors playing an important role in the removal of AGEs. An 
important first step is the degradation of AGE linked proteins to AGE-peptides by 
macrophages (19). Subsequently, adequate renal clearance capacity is necessary 
for the effective removal of these fractions of the AGEs. In renal failure, there is a 
profound decrease in clearance of AGE-free adducts (20,21). As a consequence, 
decreased renal clearance of AGEs contributes to the endogenous accumulation of 
AGEs. 
Besides the kidney, the liver may also be involved in the removal of plasma AGEs. 
Animal studies and in vitro experiments have suggested an active role of the liver in 





































cells. Sinusoidal liver cells were found to play a role in the removal of AGEs (22,23). 
Markedly elevated levels of serum AGEs have been found in patients with liver 
cirrhosis, which correlated with the severity of the disease and ameliorated by liver 
transplantation (24). To summarize, both kidney and liver failure can contribute to 
the accumulation of serum AGEs.
Pathogenetic role of AGEs
An important effect of AGEs is the crosslinking with proteins, nucleic acids and lipids, 
resulting in structural changes, malfunction and reduced breakdown. These cross-
links and accumulation on long-lived proteins, such as skin collagen or in the vascular 
basement membrane, affect the structure and function of the vascular wall resulting 
in vascular damage. Tissue accumulation of AGEs is a long-term process. Quantitation 
of the collagen-bound AGEs (in the skin) could reflect ‘metabolic memory’ over 
the past 15 years, because the lifetime of skin collagen has been estimated to be 
15-20 years (25). Another effect of AGEs is the adherence to cellular binding sites, 
resulting in depletion of cellular antioxidant defense mechanisms such as vitamin C 
and glutathione and the generation of oxygen free radicals (26,27). Vitamin C and 
glutathione are examples of the non-enzymatic antioxidant system and glutathione 
peroxidase, superoxide dismutase, catalase and the peroxiredoxin enzyme family are 
examples of the enzymatic antioxidant system. They are all part of the antioxidant 
defense system present in all aerobic organisms. Exhaustion of the antioxidant 
protective system as well as mitochondrial glycation, may enhance oxidative stress, 
introducing a vicious circle. Finally, AGEs can bind to cell membrane receptors which 
may have positive or negative effects. AGE receptors or scavenger receptors that 
enhance clearance of AGEs are part of the human immune defense system, which 
is a protection against the vascular damaging effects of AGEs. The best known pro-
inflammatory receptor for AGEs is called RAGE, a representative AGE receptor on 
endothelial cells and part of the immunoglobulin superfamily (28,29). Binding of AGE 
to RAGE could result in activation of intracellular pathways e.g. activation of NF-κB 
(nuclear factor kappa-light-chain-enhancer of activated B cells), and the subsequent 






































including the release of cytokines, finally contribute to endothelial dysfunction and 
other deleterious vascular effects (3,30-33). 
Pathogenetic role of AGEs in diabetes mellitus
Several different mechanisms concerning specific AGEs seem to play a pathogenetic 
role in the development of microvascular complications in DM. Cross-sectional studies 
have shown the association of increased AGE levels and diabetic complications. 
Skin collagen bound AGEs such as CML and pentosidine have been shown to have 
predictive value for microvascular complications, independently of glucose levels or 
recent HbA1c values (34). About 25 years after diagnosis of DM, (at least) background 
diabetic retinopathy will have developed in the majority of diabetic patients. CML 
and pentosidine skin collagen accumulation is associated with the severity of 
retinopathy in type 1 DM, independently of age and diabetes duration (2). Several 
studies have shown evidence for increased CML reactivity in diabetic retinas (35-
37). Glycation of lens crystalline and subsequent oxidation play a role in accelerated 
cataract formation in DM (38). Increased levels of pentosidine were found in the 
vitreous body of patients with diabetic retinopathy when compared to a nondiabetic 
control group (39). The importance of the role of AGEs in the development of 
diabetic retinopathy has also found evidence in animal studies with the AGE inhibitor 
aminoguanidine. Aminoguanidine prevented microaneurysm formation, pericyte 
loss, and the development of accelerated diabetic retinopathy (36). 
AGEs also play an important role in the development of diabetic nephropathy, 
which develops in approximately 40% of patients with DM. Increased levels of CML, 
pyrraline and pentosidine have been found in kidneys of diabetic patients with or 
without ESRD and circulating AGE-peptides correlates with the severity of renal 
function impairment (40,41). Experimental studies have shown the role of increased 
oxidative stress and overexpression of RAGE resulting in histological and functional 
changes contributing to diabetic nephropathy (41,42). Moreover, pharmacological 
inhibition of AGE-formation by aminoguanidine prevented the development of 
kidney lesions, albuminuria and mesangial expansion in diabetic rats (43,44).
The third microvascular complication is diabetic neuropathy, which eventually will 





































to play a pathogenetic role concerning AGEs and neuropathy: accumulation of AGEs 
in vasa nervorum resulting in wall thickening, occlusion and ischemia of nerves, and 
myelin damage with segmental demyelinisation. There is also glycation of proteins 
of the axonal cytoskelet and nerve fiber regeneration may be reduced because of 
glycation of the nerve growth factor and other growth factors (45).   
Each microvascular complication of DM has its own pathogenetic mechanism with 
AGE involvement resulting in microvascular damage.
AGEs and atherosclerosis
AGEs have been localised in atherosclerotic lesions, fatty streaks, lipid containing 
smooth muscle cells and macrophages in patients with DM, with a correlation 
between tissue AGE concentration and the severity of atherosclerotic lesions (56-
59). AGEs act directly on the arterial vessel wall by inducing cross-links on long-lived 
proteins such as collagen, which alters vascular structure and function and promotes 
vascular stiffness. Multiple potential mechanisms might be responsible for AGE 
induced enhanced atherosclerosis. AGEs capture nitric oxide and impair LDL removal 
by trapping LDL in the subendothelium and decreasing LDL receptor recognition of 
AGE-modified LDL (60). AGEs linked to apolipoprotein B impairs its hepatic clearance, 
and induces retention of LDL in the arterial vessel wall with an increased production 
of foam cells. This in turn accelerates atheromatous plaque formation (61). AGEs 
also upregulate the vascular cell adhesion molecule-1 (VCAM-1) expression by 
activating the key nuclear transcription factor NF-κB (62). Indirect evidence about 
the deleterious effects of AGEs was found in animal studies, using pharmacological 
interventions e.g. AGE cross-link breaker aminoguanidine and using sRAGE resulting 
in reduced accumulation of AGEs and suppression of vascular damage (63,64).
Pathogenetic role of AGEs in renal failure and ESRD
In patients with chronic renal failure and ESRD, irrespective of having DM or not, 
the reactive carbonyl compounds and CML levels in plasma as well as in the skin are 
markedly increased (46-49). Several mechanisms are supposed to be responsible for 
these increased serum AGE levels: impaired clearance of AGEs and AGE precursors, as 






































species. Interestingly, chronic uremia is supposed to be a state of increased oxidative 
stress with an accelerated production of CML and pentosidine even in the absence of 
glucose (50-52). Miyata postulated the existence of factors either producing unknown 
precursors or catalysing the formation of AGEs under uremic conditions. He also 
suggested that AGE accumulation including pentosidine and CML is linked to a redox 
imbalance in these conditions (13). Additionally, uremic toxins result in higher levels 
of oxidative stress, which is also facilitated by the dialysis membrane in hemodialysis, 
and activate polymorphonuclear leukocytes (53-55). All these mechanisms will lead 
to increased serum AGE levels, finally resulting in an accelerated accumulation of 
tissue AGEs which in turn contributes to vascular damage. 
Assessment of AGEs
It is a challenge to determine the best and most proper assessment of the level of tissue 
AGE accumulation, because the structure of AGEs is complex and heterogeneous, 
and each technique has its own limitations. 
Serum AGEs
Different assays concerning the measurement of serum AGE levels have been 
developed, but these assays are only applicable to AGEs with known biochemical 
structures. These assays do not represent the whole group of serum AGEs. For 
example, the immunoassay method, using different antibodies against different 
AGEs in an ELISA is not very laborious, is cheap and feasible for clinical use, but 
reproducibility and sensitivity still remains a problem (65,66). On the other hand, 
liquid chromatography – mass spectrometry (LC-MS) is a more specific and reliable 
method for measuring serum AGE levels, but this technique is expensive and time-
consuming.
All of the techniques of serum AGE level measurement do not accurately reflect the 
accumulation of tissue AGEs (67-72). Turnover of AGE-linked proteins in serum is 
much higher and is more dependent on renal clearance than the AGE crosslinked 





































AGEs with tissue AGE accumulation is unclear. Moreover, the reproducibility of many 
(immune) assays between different laboratories is also rather poor. 
Tissue AGEs
Assessment of AGEs in skin biopsies comprises invasive and elaborate methods: 
extensive preparation of samples, high-performance liquid chromatography 
(HPLC), LC-MS or tandem MS. It also includes the determination of collagen linked 
fluorescence and the protein cross-linking index as markers of tissue AGEs. The 
latter two methods both provide an indirect quantitative measure of tissue AGE 
accumulation. The fluorescence method has a proven association with (diabetic) 
complications (35,73). The disadvantages of this method are the interference with 
non-AGE fluorophores and there is no detection of non-fluorescent AGEs such as 
CML and pyrraline. The method of collagen crosslinking has a low specificity, is only 
valid to collagen rich tissue, and its reproducibility is unclear. Because of the invasive 
character of both methods, they are not feasible for AGE monitoring.
Tissue AGEs can also be measured by the skin autofluorescence reader, an easily 
applicable, and noninvasive instrument, the use of which is not time consuming. Skin 
autofluorescence (AF) has been validated against AGE measurements in dermal tissue 
obtained by skin biopsies from the site of the skin AF measurement, taken in patients 
on hemodialysis, DM and healthy controls, and its reproducibility is reasonably well 
showing a mean relative error in AF of 5.0% (74-76). 
The autofluorescence reader
In 1996, a serendipitous finding of Jager et al. led to the development of the AF 
reader. Unexpectedly high baseline levels of skin AF were measured by a fluorescence 
microscope in diabetes patients compared to healthy controls, while measuring 
capillary sodium fluorescein leakage to investigate capillary permeability (77,78). 
This remarkable observation was the first step to the development of a non-invasive 
device reflecting tissue accumulation of AGEs. The so-called skin AF reader, eventually 
developed into the commercially available AGE reader (Diagnoptics Technologies, 






































This technique is based on the fluorescence properties of certain AGEs and expresses 
the level of skin AF. The AGE reader illuminates a skin surface of ~ 4 cm2 at the volar 
side of the arm, 10 cm below the elbow fold and uses an excitation UV-A light source 
with the intensity between 350 – 420 nm (maximum intensity at 370 nm). Emission 
light and reflected excitation light from the skin are measured with a spectrometer in 
the 300-600 nm range, figure 2b. Because of the influence of skin pigmentation, AF 
was computed by dividing the average light intensity of the emission spectrum by the 
average light intensity of the excitation spectrum. The level of skin AF is multiplied 
by 100 and is expressed in arbitrary units. In patients with dark skin, melanin in the 
epidermis will absorb a considerable part of the UV-A light source, resulting in lower 
reflection of the excitation UV light and less UV light penetration in the dermal layer 
of the skin, finally resulting in less fluorescence. Moreover, part of the fluorescent 
light itself will also be absorbed by melanin. Therefore patients with Fitzpatrick class 
V-VI skin type were excluded because of the limitation of the prototype AF reader to 
measure accurately in dark skin types and measurements with skin reflection below 
10% were discarded as well. Recently, a newly developed AF reader has the capacity 
to measure in dark skin types (79). Another remark concerning skin AF measurement 
is the measurement of other fluorophores than fluorescent AGEs, acting as a 
confounder. Furthermore, there are non-fluorescent AGEs present in the skin as well, 
which may contribute to the overall effects of AGE accumulation. 
Figure 2a. Skin autofluorescence reader in a clinical setting. Data from the integrated 
spectrometer of the AGE reader is passed on to a computer by USB connection and the 




















































Figure 2b. Schematic diagram of the skin autofluorescence reader or AGE reader. The 
excitation light source is a black light TL tube. Two calibration measurements are performed 
with a closed shutter: one against a white reflection standard and one dark measurement. 
After opening of the shutter, the forearm skin of the subject is illuminated. Emission light and 
reflected excitation light from the skin within a range of 300 – 600 nm is transmitted by a fiber 
probe to the integrated spectrometer.  
Objectives
An important aim of this thesis was to assess the possible predictive value of skin 
AF for (micro)vascular morbidity and mortality in two high risk patient groups: type 
2 DM and ESRD patients. The studies assessed in Part one of the thesis included 
type 2 DM patients who were all participating in a shared-care project of the Zwolle 
Outpatient Diabetes project Integrating Available Care (ZODIAC) Study.
We investigated the possible predictive value of skin AF for the development 
of microvascular complications in a type 2 DM patient group (Chapter 2). In an 
observational setting, we prospectively analyzed the relationship between the level 
of skin AF and the risk of developing microvascular complications of DM (retinopathy, 
neuropathy and nephropathy), both separately and combined. 
Another objective of this thesis was to study whether glycemic control could predict 
the change in tissue AGE accumulation during time in type 2 DM (Chapter 3). 






































sequential HbA1c measurements, were studied in relationship to skin AF in type 2 
diabetes patients recruited from the earlier mentioned cohort participating in the 
ZODIAC study.
The ZODIAC-28 study was performed to investigate whether serum peroxiredoxin 4, 
as part of the antioxidant defense system, was associated with cardiovascular and 
all-cause mortality in the same population of type 2 diabetes patients as already 
mentioned (Chapter 4).
Finally, the ZODIAC-10 study was performed as a life expectancy study in type 2 DM 
with the aim to assess present-day life expectancy of these diabetes patients in the 
ongoing cohort of the ZODIAC study compared to the general Dutch population 
(Chapter 5). 
Part two of this thesis, concerned another high risk patient group: patients with 
chronic kidney disease and/or ESRD who were on hemodialysis. Chapter 6 defines 
the relationship between AGEs, autofluorescence and renal function in an editorial 
comment with the inclusion of original data about the correlation between skin AF 
and the estimated glomerular filtration rate in type 2 DM patients. 
Chapter 7 is a review article about skin AF as a measurement of AGEs and as a risk 
marker in chronic kidney disease. Finally, we studied the predictive role of skin AF 
on overall and cardiovascular mortality in a hemodialysis patient group (Chapter 8). 
These patients were recruited from the hemodialysis centre of the Isala Clinics in 
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PART I 
CARDIOVASCULAR RISK AND ITS DETERMINANTS




SKIN AUTOFLUORESCENCE: A TOOL TO IDENTIFY 
TYPE 2 DIABETIC PATIENTS AT RISK FOR 
DEVELOPING MICROVASCULAR COMPLICATIONS
Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, 
Smit AJ, Gans RO, Bilo HJ.






































Objective Skin autofluorescence (AF) is a noninvasive measure of the level of tissue 
accumulation of advanced glycation endproducts, representing cumulative glycemic 
and oxidative stress. Recent studies have already shown a relationship between skin 
AF and diabetic complications, and its predictive value for total and cardiovascular 
mortality in type 2 diabetes mellitus. Our aim was to investigate the predictive value 
of skin AF for the development of microvascular complications in type 2 diabetes 
mellitus. 
Research Design and Methods At baseline, skin AF of 973 well-controlled type 2 
diabetes patients was noninvasively measured with an autofluorescence reader. 
The aggregate clinical outcome was defined as the development of any diabetes-
associated microvascular complication of 881 surviving patients which was assessed 
at baseline and at the end of follow-up. Single endpoints were the development of 
diabetes associated retinopathy, neuropathy and (micro)albuminuria.
Results After a mean follow-up period of 3.1 years, baseline skin autofluorescence 
was significantly higher in patients who developed any microvascular complication, 
neuropathy or (micro)albuminuria, but not in those who developed retinopathy. 
Multivariate analyses showed skin AF as a predictor for development of any 
microvascular complication along with HbA1c, for development of neuropathy along 
with smoking, and for development of (micro)albuminuria together with sex, HbA1c 
and diabetes duration. Skin autofluorescence did not have predictive value for the 
development of retinopathy, albeit diabetes duration did. 
Conclusions Our study is the first observation of skin autofluorescence measurement 
as an independent predictor for the development of microvascular complications in 








































Hyperglycemia, individual susceptibility and lifestyle are three key factors that play 
an important role in the development of microvascular disease in diabetes mellitus. 
One of the consequences of hyperglycemia and attendantly increased generation of 
free radicals is the increased formation of advanced glycation endproducts (AGEs), 
besides the increased polyol and hexosamine fluxes, and activation of protein 
kinase C, which all contribute to tissue damage in diabetes (1,2). Those AGEs can 
be described as the final products of slowly occurring non-enzymatic glycation of 
proteins that form cross-links with long-lived proteins such as collagen (the so called 
Maillard reaction). They may also accumulate as a result of oxidative stress-related 
glycoxidation and lipoxidation pathways. 
In the Diabetes Control and Complications Trial (DCCT), long-term intensive 
treatment compared with conventional treatment of hyperglycemia in type 1 diabetic 
patients improved glycemic control, and delayed the progression of microvascular 
complications (3). The UK Prospective Diabetes Study and other prospective 
studies have also shown an association between hyperglycemia and increased risk 
of microvascular complications in type 2 diabetes (4-6). The DCCT Skin Collagen 
Ancillary Study Group showed the association of long-term intensive treatment of 
hyperglycemia, as compared with conventional treatment, with lower levels of AGEs 
in skin collagen and they showed that these AGE levels in skin biopsies predicted 
the risk of development or progression of microvascular disease in type 1 diabetes 
mellitus, even after adjustment for HbA1c (7,8). 
A newly described noninvasive method to assess tissue AGEs concerns skin 
autofluorescence. This method is based on the specific fluorescence characteristics 
of AGEs and has been validated against specific AGE levels in skin biopsies in patients 
with diabetes or on hemodialysis, and in healthy control subjects (9,10).
Recently, the relationship between skin autofluorescence, reflecting AGE 
accumulation, and outcome has been studied in type 2 diabetes. Besides its 
relation with chronic diabetes complications (in cross-sectional analyses), skin 
autofluorescence has also shown independent predictive value for cardiovascular 
mortality and morbidity in patients with type 2 diabetes and in patients with end-





































In this study, we analyzed whether skin autofluorescence, as a marker of AGE 
accumulation, can predict the development of microvascular complications in a type 
2 diabetic population.
Research Design and Methods
Patients
Between May 2001 and May 2002, 973 primary care type 2 diabetic patients were 
included in the study cohort and had a skin autofluorescence measurement. The 
included patients were all participating in a shared-care project of the Zwolle 
Outpatient Diabetes project Integrating Available Care (ZODIAC) Study and have 
also been described elsewhere (11). During follow-up, data of 967 patients were 
analyzed for this study (6 patients were lost to follow-up). Eighty-six patients died 
before the end of follow-up and this subgroup will be addressed separately from the 
surviving 881 patients. Patients with a Fitzpatrick class V-VI skin type were excluded, 
because of the autofluorescence reader’s limitation to measure accurately in dark 
skin types (13-15). All participating patients visited the outpatient clinic at least once 
a year. Follow-up ended at January 2005. All of the included patients had given their 
informed consent, and approval by the local ethics committee had been obtained. 
Skin autofluorescence 
The autofluorescence reader (prototype of the current AGE Reader; DiagnOptics, 
Groningen, the Netherlands) illuminates a skin surface of ~4 cm2, guarded against 
surrounding light, with an excitation light source with peak intensity at ~370 nm. 
Emission light and reflected excitation light from the skin are measured with a 
spectrometer in the 300-600 nm range, using a glass fiber. AF was computed 
by dividing the average light intensity of the emission spectrum 420-600 nm by 
the average light intensity of the excitation spectrum 300-420 nm, multiplied by 
hundred and expressed in arbitrary units (AU). Skin autofluorescence of all patients 
was assessed at the volar side of the arm, 10 cm below the elbow fold. Six diabetes 
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autofluorescence reader devices. The autofluorescence reader has been validated 
and more extensively been described in previous studies (9,11).
Data collection 
Clinical data and laboratory results were obtained at the time of the baseline skin AF 
measurement. Serum creatinine, nonfasting lipids (total cholesterol, LDL cholesterol, 
HDL cholesterol, and triglycerides), and urinary albumin and creatinine were 
measured according to the standard laboratory procedures. HbA1c was measured 
with a Primus CLC-385 using boronate affinity chromatography and high-performance 
liquid chromatography (reference value 4.0 – 6.0%). Blood pressure measurement 
was a single measurement obtained after 5-minutes rest with the patient in seated 
position, using an aneroid device. At each visit to the outpatient clinic and at the 
end of follow-up, the absence or presence of retinopathy, neuropathy, and (micro)
albuminuria was assessed.
Clinical end points 
The aggregate clinical end point was the development of any diabetes-associated 
microvascular complication, which was defined as the presence of at least one of 
the following diabetes complications according to the American Diabetes Association 
definitions: retinopathy, neuropathy and/or (micro)albuminuria (16). The single 
clinical end points were described as the development of retinopathy, neuropathy 
or (micro)albuminuria. Retinopathy was determined by an ophtalmologist based on 
retinal photography. Presence of at least background retinopathy was assumed to 
imply retinopathy. Neuropathy was examined using a 5.07/10 g Semmes-Weinstein 
monofilament, applied on the dorsum of both feet at three different, non-callused 
areas (first toe, and first and fifth distal metatarsal bone). Neuropathy was considered 
in case of diminished sensibility, which was defined in case of at least two incorrect 
responses after 3 applications at each area (two real and one false application) 
(17,18). (Micro)albuminuria at baseline was defined as an albumin-to-creatinine 
ratio >2.5 mg/mmol for men and >3.5 mg/mmol for women in two subsequent urine 
samples or once in the year before baseline while using an ACE-inhibitor at baseline 





































to-creatinine ratio >2.5 mg/mmol for men and >3.5 mg/mmol for women in two 
urine samples (one in the year before and one at the moment during follow-up) or 
an abnormal level of the albumin-to-creatinine ratio in the year before the end of 
follow-up whilst using an ACE-inhibitor at follow-up. 
Statistical analysis
One-way ANOVA using posthoc multiple comparisons (with Bonferroni correction) 
was used to compare mean skin autofluorescence between subgroups of 
microvascular complications in the 881 surviving patients. Subgroups are as follows: 
1) no microvascular complication at baseline or at follow-up, 2) no microvascular 
complication at baseline but a microvascular complication at follow-up and 3) a 
microvascular complication at baseline and at follow-up.
Univariate and multivariate multinominal regression analyses were performed to 
determine the relationship of skin autofluorescence to the presence or development 
of microvascular disease. Patients without signs of microvascular complications at 
baseline or at follow-up formed the reference categories in these calculations. In the 
multivariate analyses, we controlled for potential confounding risk factors for the 
development of microvascular complications which were derived from the UKPDS 
findings, including sex, diabetes duration, HbA1c, current smoking, systolic blood 
pressure, HDL cholesterol, LDL cholesterol and triglycerides with the addition of BMI 
(4). 
Odds ratios (ORs) (CI 95%) for skin autofluorescence were calculated in the univariate 
and multivariate analyses. P values <0.05 were considered statistically significant.
Results
The baseline characteristics of the surviving study population including mean skin 
autofluorescence of the total group are shown in Table 1. Mean age of our study 
population was 66 years, 46% of whom were male, with a relatively short median 
diabetes duration of 4.0 years (interquartile range 1.5 – 8.1 years). Eighty-five 
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or oral agents; the other 15% of patients received insulin or combined insulin/oral 
agent treatment. 
Table 1. Characteristics of the type 2 diabetic patients. 
Characteristic  
n 881
Age (years) 66 ± 11
Sex (male/female) 406/475
Smoking (%) 19
BMI (kg/m²) 29.4 ± 4.8
Systolic blood pressure (mmHg) 146 ± 20
Diabetes duration (years) 4.0 (1.5-8.1)
HbA1c (%) 6.6 (6.0-7.6)
Creatinine (µmol/l) 95 ± 19
Creatinine clearance (ml/min) 77 ± 27
Urinary albumin-to-creatinine ratio 1.41 (0.76-3.79)
Total cholesterol (mmol/l) 5.2 ± 1.0
HDL cholesterol (mmol/l) 1.3 ± 0.3
LDL cholesterol (mmol/l) 2.9 ± 0.9









Macrovascular disease (%) 37
Skin autofluorescence (total group) (AU) 2.74 ± 0.7
Values are mean ± SD or median (interquartile range) unless otherwise indicated. Reference 
values of the laboratory: HbA1c 4.0-6.0 %, creatinine 70-110 µmol/l, creatinine clearance 
(Cockcroft-Gault formula) 80-120 ml/min, urinary albumin-to-creatinine ratio 0-2.5, total 
cholesterol 3.5-5.0 mmol/l, HDL cholesterol 0.9-1.7 mmol/l, LDL cholesterol 3.6-4.4 mmol/l, 
and triglycerides 0.6-2.2 mmol/l.
In the 881 survivors, the prevalence of retinopathy, neuropathy and (micro)
albuminuria at baseline was 19, 24 and 24%, respectively, resulting in an overall 
percentage of patients with a diabetes associated microvascular complication of 
50%. 
Table 2 shows the mean baseline skin autofluorescence of the 881 survivors 
subdivided in groups with continued absence or presence or the development of 





































years, 61 patients (7.0%) developed retinopathy; their baseline skin autofluorescence 
did not differ from skin autofluorescence levels of patients who did not show or 
already had retinopathy at baseline. However, skin autofluorescence was higher 
in the patient groups who developed neuropathy or (micro)albuminuria compared 
to those without these complications. At follow-up, newly developed neuropathy 
was diagnosed in 7.5% and newly developed (micro)albuminuria was found in 
10.1% of patients; 12.5% of the population developed at least one microvascular 
complication. Skin autofluorescence at baseline was also significantly higher in the 
patient groups that developed any microvascular complication or who already had a 
microvascular complication at baseline compared with patients who did not develop 
any microvascular disease. 
Table 2. Mean ± SD skin autofluorescence at baseline and mean differences between groups.
        
            






















































































Data are means ± SD of skin autofluorescence in AUs within the group or mean differences 
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Multinominal logistic regression analysis showed that skin autofluorescence 
was a strong predictor of the development of the aggregate of microvascular 
complications [OR 2.05 (95% CI 1.51-2.80), p<0.001]. Skin autofluorescence was 
significantly associated with the development of retinopathy [1.42 (1.01-1.99), 
p=0.042], neuropathy [1.59 (1.15-2.19), p=0.005], and (micro)albuminuria [1.73 
(1.28-2.34), p<0.001]. After correction for the confounding risk factors, baseline skin 
autofluorescence still appeared to be significantly associated with the development 
of these end points, except for retinopathy [1.21 (0.83-1.74), p=0.32] (Table 3). 
Diabetes duration at baseline was the only significant independent variable for the 
development of retinopathy in this multivariate analysis [1.10 (1.06-1.15), p<0.001]. 
Surviving smokers less often developed neuropathy compared with non-smokers. 
In the nonsurviving group (86 patients), 70% had a microvascular complication at 
baseline; there were 23 non-surviving smokers. Seventy percent of the non-surviving 
smokers already had a microvascular complication at baseline, and 13% of the non-
surviving smokers developed a microvascular complication before they died.
When baseline skin autofluorescence levels are categorized in subgroups of 
practically feasible levels of skin autofluorescence (three categories in rounded 
tertiles: skin autofluorescence < 2.35 AU, 2.35 ≤ skin autofluorescence < 3.00 AU, 
skin autofluorescence ≥ 3.00 AU); those in the category skin autofluorescence ≥3.00 
AU do have a higher chance to develop a microvascular complication compared to 
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Table 4. Prediction of newly developed microvascular complications subdivided into three skin 
autofluorescence (AF) groups. 
Microvascular 
complication
n* Skin AF 
< 2.35 AU




Retinopathy  708 15/241 (6.2) 18/251 (7.2) 28/216 (13.0)
Neuropathy 662 11/219 (5.0) 27/247 (10.9) 28/196 (14.3)
(Micro)albuminuria  657 18/225 (8.0) 31/253 (12.3) 38/179 (21.2)
Any 431 23/161 (14.3) 41/167 (24.6) 45/103 (43.7)
Data are n (%) of newly developed microvascular complications of subgroups compared to 
the group who did not develop a microvascular complication. *Patients who did not have a 
complication at baseline. Subgroups of skin AF are tertiles rounded to a practical level.
Conclusions
Our study provides the first evidence that skin autofluorescence is an independent 
predictor of the development of microvascular complications in a population of 
patients with well-controlled type 2 diabetes. Separately, this also holds for the 
development of neuropathy and (micro)albuminuria (and in univariate analysis 
for retinopathy). This noninvasive marker of tissue AGE accumulation may reflect 
the deleterious effects of long-term glycemic and oxidative stress. Meerwaldt et 
al. recently showed that skin autofluorescence is a predictor of 5-year coronary 
heart disease and mortality in diabetes (12). The present study shows that skin 
autofluorescence also has a predictive value for the development of microvascular 
complications that, in the analysis of this study, is superior to that of many other 
commonly used risk predictors, such as diabetes duration and HbA1c, in type 
2 diabetes. This conclusion is applicable for primary care type 2 diabetic patients 
treated according to current standards, which is the large majority of type 2 diabetes 
patients in the Netherlands.
The DCCT/EDIC (Epidemiology of Diabetes Interventions and Complications) substudy 
already showed the predictive value for skin AGE levels obtained from skin biopsies 
for the progression of microvascular complications in patients with type 1 diabetes 
(8). Our study population consisted of type 2 diabetic patients with skin AGE level 
assessment by means of a noninvasive, rapid method. Another difference is that 





































of microvascular complications. The limited follow-up period; the low rate of clearly 
classifiable progression of the microvascular complications, especially retinopathy; 
and the confounding role of introduced medication made us decide to restrict our 
study to the evaluation of the development of microvascular complications and not 
to address progression of these diabetes complications.
In retinopathy, skin autofluorescence turned out to have no prognostic value in the 
multivariate analysis. Possible explanations are the short follow-up period and the 
smaller amount of patients who developed retinopathy versus the other complications. 
Moreover, the different pathophysiologic mechanisms of microvascular damage in 
the different organs (retina, kidneys and neurons) could play a role in the differences 
in incidence rates of outcomes. In particular, the pathobiology of retinopathy might 
be different from that of the kidney and neurologic system as a result of a different 
role of vascular endothelial growth factor as a possible mediator for proliferation 
(20).
(Micro)albuminuria is an early clinical sign of diabetic nephropathy; when left 
untreated, it predicts a high risk for the development of progressive renal damage, 
which eventually may lead to end stage renal disease. Progressive renal disease is 
also associated with a vastly increased cardiovascular risk. This study defined (micro)
albuminuria as a sign of microvascular complication with the intention to reflect 
early stages of diabetic nephropathy. 
In the predictive analyses, the non-surviving patients were excluded from the analyses. 
These non-survivors had markedly increased skin autofluorescence values, but they 
also had a very high prevalence of microvascular complications at baseline (70%), so 
this does not reduce the strength of the relation between skin autofluorescence and 
microvascular complications. 
Ethnicity is one of the mentioned UKPDS confounding risk factors for the 
development of microvascular disease. Because of the limitation of measuring skin 
autofluorescence in dark skin types associated with the prototype of the AGE reader 
used in the present study, individuals with dark skin had to be excluded. Over 95% 
of the participants were Caucasian; therefore, ethnicity was not taken into account 
in the analyses. Further developments of the AGE reader may hopefully enable 
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Lutgers et al. previously described the other limitations of the autofluorescence 
reader as a marker of tissue AGE accumulation: non-fluorescent AGEs will not be 
measured with the autofluorescence reader, and other tissue components that 
fluoresce in the same range of wavelength might be confounders (11).
In conclusion, our study confirms skin autofluorescence as a helpful clinical method 
to identify type 2 diabetic patients at risk for (developing) any microvascular 
complication, neuropathy and (micro)albuminuria. Further investigation with longer 
follow-up needs to be done to assess whether skin autofluorescence is a factor 
in the development of diabetic retinopathy and to assess the relationship of skin 
autofluorescence and the progression of microvascular complications. Its non-
invasive and time-saving application makes the autofluorescence reader an easy 
clinical tool that is useful in the outpatient clinic in risk assessment and for monitoring 
changes in accumulation of tissue AGEs reflecting long-term glycemic stress.
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CHAPTER 3
SKIN ADVANCED GLYCATION ENDPRODUCTS 
ACCUMULATION IS POORLY REFLECTED BY 
GLYCEMIC CONTROL IN TYPE 2 DIABETIC 
PATIENTS (ZODIAC-9)
Gerrits EG, Lutgers HL, Kleefstra N, Groenier KH, Smit AJ, 
Gans ROB, Bilo HJG 






































Background Glycemic memory can be reflected by tissue accumulation of advanced 
glycation endproducts (AGEs). In type 1 diabetes mellitus (T1DM) patients, 
hemoglobine A1c (HbA1c) levels over various time periods poorly predicted the 
accumulation of different AGEs in skin biopsies. Our aim was to investigate whether 
HbA1c assessments can predict the change in skin AGEs during time in type 2 diabetes 
mellitus (T2DM).
Methods We included 452 T2DM patients participating in a shared-care setting, who 
are screened annually for HbA1c and diabetic complications. Baseline and follow-up 
levels of skin AGEs were assessed with a validated noninvasive autofluorescence (AF) 
method which is based on the fluorescence characteristics of certain AGEs. 
Results Our study population had a mean age of 65 years and 54% were female. After 
a mean follow-up duration of 3.3 years, linear regression analyses showed weak 
relationships among different assessments of HbA1c (baseline, maximum, mean and 
variance of HbA1c) and skin AF at follow-up. Baseline skin AF and age were predictors 
of skin AF at follow-up, but diabetes duration, smoking, and creatinine were of less or 
no predictive value for skin AF at follow-up. 
Conclusions In our T2DM population, integrated HbA1c assessments over years 
poorly predict the change in skin AGE level measured by skin AF. These findings 
agree with results in patients with T1DM. This suggests either the need for longer 
exposure to glucose disturbances to change tissue AGEs or other mechanisms, such 
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Introduction
Short-term glycemic memory can be reflected by hemoglobine A1c (HbA1c), which 
represents the degree of glycemic control over the last 6 to 8 weeks. Another more 
long-term glycemic index encompasses the level of tissue accumulation of advanced 
glycation end products (AGEs) (1). These stable end products of glycation of proteins 
are formed nonenzymatically in the Maillard reaction from Amadori products such 
as HbA1c. AGEs can also be formed by reactive carbonyl compounds (e.g. glyoxal, 
methylglyoxal, arabinose, glycoaldehyde) in conditions of enhanced oxidative stress 
in general. AGEs form cross-links in and accumulate on long-lived proteins such as 
skin collagen, which has an estimated lifetime of 15 – 20 years. Quantization of these 
collagen-bound AGEs could provide information about cumulative glycemic and 
oxidative stress over several years. Part of this metabolic process is a consequence of 
poor metabolic control over a considerable period, probably years. 
Important evidence regarding the relationship between poor metabolic control and 
the development or progression of diabetic complications has been found earlier 
in T1DM in the Diabetes Control and Complications Trial (DCCT) and in T2DM in the 
United Kingdom Prospective Diabetes Study (UKPDS) study during the nineties (2,3). 
Relevance of the glycated collagen products compared to HbA1c, both as markers of 
diabetic complications, has been investigated in a DCCT – Epidemiology of Diabetes 
Interventions and Complications (EDIC) substudy (1). Long-term intensive treatment 
compared to conventional treatment of type 1 diabetes patients resulted in lower 
skin collagen glycation, glycoxidation, and cross-links. The accumulation of collagen 
AGEs, as measured in skin biopsies, explained an unexpectedly high percentage of 
variance in the incidence of diabetic complications, also after adjustment for HbA1c 
levels. Monnier et al. also found that the AGE accumulation in skin biopsies of type 
1 diabetic patients was poorly predicted by HbA1c levels over several different time 
periods (2).
Advanced glycation end product accumulation can be quantified by tissue 





































autofluorescence reader (AFR) or currently AGE reader. This newly developed 
device measures certain tissue AGEs, with the concept of reflecting metabolic 
control over several years, and has already been established as a risk marker for 
micro- and macrovascular complications and mortality in T2DM (4,5). Controlling 
glycemic and metabolic status is an important issue in preventing long-term diabetic 
complications and it is not clearly defined which marker for metabolic control over a 
certain period is the best predictor in relation to the development of chronic diabetic 
complications. We hypothezised that the accumulation of AGEs in type 2 diabetes 
patients can be predicted by the course of HbA1c during a certain period prior to the 
skin autofluorescence (AF) measurement. The aim of our study was to investigate to 
what extent skin AF, reflecting tissue AGE accumulation, can be predicted by different 
integrated assessments of HbA1c in type 2 diabetic patients. 
Methods
Study Population
Subjects were recruited from a large type 2 diabetes cohort participating in the Zwolle 
Outpatient Diabetes project Integrating Available Care (ZODIAC)-study (6). Baseline 
skin AF measurements were performed in a cohort of 973 patients between May 
2001 and May 2002 (7). At the end of follow-up, from June 2004 untill October 2005, 
a second skin AF was assessed randomly in 452 patients from the initial population 
of 973 patients who were still visiting the diabetes outpatient clinic. Because of the 
limitation of the applied AFR to measure accurately in dark skin types, patients with 
a Fitzpatrick class V-VI skin type were excluded from the beginning. All participating 
patients visited the outpatient clinic annually and all of them had given informed 
consent. Approval by the local ethical committee had been obtained. 
Autofluorescence Reader
Assessment of tissue AGEs by the AFR device, a prototype of the current AGE reader 
(DiagnOptics Technologies BV, Groningen, The Netherlands), is based on a technique 
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and expresses the level of skin AF. This non-invasive measurement is obtained 
by positioning the ventral side of the lower arm on a window in a box containing 
an excitation ultraviolet A light source with a peak wavelength around a 370 nm 
excitation light, integrated over the 300 to 420 nm range. Reflected light from the 
skin and emission light in the 420 to 600 nm range are measured with an integrated 
spectrometer. Dividing the average light intensity of the emission spectrum by the 
average light intensity of the excitation spectrum expresses the skin AF level in 
arbitrary units (AU). To calculate skin reflection, white reference measurements 
(with a white Teflon block, assuming 100% reflectance) were performed before every 
measurement. Over all AF measurements, the mean age-corrected AF per measuring 
month, per examiner, and per AFR system did not differ significantly. The AFR has 
been described more in detail elsewhere (8). 
Clinical data and Laboratory Assessments
Clinical data were obtained on the date of the first skin AF measurement; these data 
were derived from the Diabetic Electronic Monitoring System (DEMS) containing 
data of all patients in the shared-care project (6). Laboratory assessments were 
measured according to the standard hospital procedures of the Isala Clinics, Zwolle, 
The Netherlands. HbA1c was measured with a Primus CLC-385 using boronate affinity 
chromatography and high-performance liquid chromatography (reference value 4.0 
– 6.0%). The presence of microvascular disease was defined as the occurrence of 
at least one of the following diabetic complications: retinopathy, neuropathy and/
or nephropathy. We used the albumin-to-creatinine ratio (ACR) in our definition of 
nephropathy. The relationship between skin AF and ACR was shown in the original 
study population, and the predictive value of skin AF for the development of 
nephropathy has been studied as well (4,7). Macrovascular disease was defined as 
the presence of at least one aspect of the following cardiovascular complications: 
coronary heart, cerebrovascular and/or peripheral vascular disease. All complications 
are described in detail elsewhere (7).






































Comparing means of skin AF between patients with and without a diabetic 
complication was performed by analysis of variance.
Linear regression was used to determine the relationship between skin AF at follow-
up and various HbA1c measures. The different integrated assessments of HbA1c 
used in the analyses were: the variance of HbA1c, mean HbA1c, maximum HbA1c, 
and HbA1c at baseline. Mean and variance of HbA1c were calculated over the 
annually assessed HbA1c measurements between baseline and the end of follow-
up. Maximum HbA1c is the highest HbA1c level of the annually assessed HbA1c 
measurements between baseline and the end of follow-up.
Adjustment for baseline skin AF was performed in all the analyses. In multivariate 
regression, in addition to baseline skin AF, adjustments for age, diabetes duration, 
creatinine, and smoking were made (all variables were assessed at baseline). These 
variables are all independently related to skin AF and could all affect the rate of 
formation and accumulation of AGEs during years (7). 
Results
Baseline characteristics are shown in Table 1. Mean age was 65 years with 255 (54%) 
female patients. The mean follow-up duration was 3.3 ± 0.4 years. At baseline, 
patients were well-controlled with a mean HbA1c of 6.8 ± 1.2 % and mean HbA1c at 
follow-up was 7.0 ± 1.0 %. Patients with either a microvascular or a macrovascular 
complication had higher levels of skin AF at baseline (Table 2). 
The total amount of annually collected samples of HbA1c per patient was minimal 3 
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Table 1. Baseline characteristics.
Patient characteristic N = 452 
Age (years) 65 (11)
Gender (F/M) 244/208 (54%/46%)
Smoking (%) 19
Body Mass Index (kg/m2) 29.5 (4.9)
Systolic bloodpressure (mmHg) 145 (20)
Diastolic bloodpressure (mmHg) 81 (10)
Diabetes duration (years) 3.6 (1.5 – 7.5)a
HbA1c (%) 6.8 (1.2)
Creatinine (µmol/l) 94 (17)
Total cholesterol (mg/dl) 197 (37)
Microvascular disease (%) 46
Macrovascular disease (%) 35
Skin AF at t0 (AU) 2.71 (0.69)
Skin AF at t follow up (AU) 2.79 (0.77)
Values are expressed as mean (SD). aMedian and interquartile range. Reference values of the 
laboratory: HbA1c 4.0-6.0 %, creatinine 70-110 µmol/l, total cholesterol 135-193 mg/dl. AU, 
arbitrary units.
Table 2. Mean skin AF ± standard deviation (arbitrary units) of patients with or without a 
micro/macrovascular complication.
Complication Yes (n) No (n) p value
Microvascular 2.81 ± 0.70 (208) 2.63 ± 0.67 (244) 0.005
Macrovascular 2.91 ± 0.74 (156) 2.61 ± 0.63 (296) <0.001
The relationship between skin AF at follow-up (adjusted for the also presented skin 
AF at baseline) and the various assessments of HbA1c are shown in Table 3. Skin AF 
at follow-up showed weak, but significant relationships with all different integrated 
assessments of HbA1c: regression coefficients < 0.1; p ≤ 0.025 [with addition of 
baseline skin AF: overall adjusted R2 ~ 0.45; p<0.001]. Table 4 shows the linear 
regression analyses of skin AF at follow-up versus different integrated assessments 
of HbA1c with adjustment for baseline skin AF, age, diabetes duration, creatinine 
and smoking. In all analyses adjusted R2 of skin AF at follow-up was 0.48 (p<0.001), 
although the regression coefficients of all the different integrated HbA1c assessments 
were low (maximum 0.069) and, therefore, added little prognostic value to skin AF 
level at follow-up. Skin AF level at baseline proved to be the best predictor of skin AF 
at follow-up (regression coefficient = 0.65 for mean HbA1c, maximum HbA1c, HbA1c 
at baseline, and 0.66 for the variance of HbA1c; p<0.001). Age and creatinine were of 
less predictive value than skin AF at baseline. In these models diabetes duration and 





































Table 3. Linear regression models of skin AF at follow up (adjusted for skinAF at t0) versus 








































Table 4. Multivariate Linear regression models of skin AF at follow up (adjusted for baseline 









Variance of HbA1c 


































































































































Skin AGE accumulation and glycemic control
3
Discussion
This study showed that skin AF, reflecting tissue AGE accumulation and proposed 
as an exponent of glycemic long-term memory, is poorly predicted by the degree 
of short-term glycemic control in a type 2 diabetes population. The variance, mean, 
maximum and baseline measurements of HbA1c during a 3.3-year period prior to the 
skin AF measurement at the end of the follow-up period, were all of little value for 
predicting the change in AGE accumulation. These findings confirm the observations 
by Monnier and colleagues in the DCCT-EDIC cohort in T1DM (2). In the DCCT – EDIC 
substudy analyses of skin collagen variables against HbA1c levels at various time 
points regarding the date of biopsy were adjusted for age and diabetes duration only 
(1). In our cohort, age and skin AF at baseline were the most pronounced factors that 
influenced skin AF at follow-up, which is not surprising. A stable or small increase of 
the accumulation of AGEs was seen during the relatively short follow-up period. This 
also confirms the slow process of formation and accumulation of AGEs in human 
tissue, but could also be due to the on average well-controlled study population 
(mean HbA1c of 6.8%). The mean increase in skin AF of 0.08 AU over 3.3 years is also 
in line with the similarly small age decade-related differences in skin AF levels in our 
previous cross-sectional study in the same cohort (7). 
Renal function as reflected by serum creatinine, affects the capacity for AGE removal 
and, therefore, plays an independent role in the accumulation of tissue AGEs. In 
the present study, it was indeed confirmed that serum creatinine contributes to the 
change in skin AF at follow-up. Cross-sectional data showed that smoking resulted in 
increased skin AF levels in both T2DM and controls, but in the present longitudinal 
analyses, smoking at baseline did not correlate to skin AF levels at follow-up (7). This 
could be due to the short follow-up period and/or to the strict diabetes treatment 
regimen of patients participating in the shared care project, which included 
stimulation of patients to stop smoking. The percentage of smokers was low in our 
cohort. Because tobacco smoke is a source of precursors of AGEs and free radicals, 
which both enhance AGE formation and accumulation, cessation of smoking could 





































In our study, unfortunately, no data were available on the effects of short-term 
glycemic variability nor on the degree of oxidative stress. Hyperglycemia is a well-
known endogenous source of oxidative stress (11,12). Monnier and associates 
confirmed that glucose fluctuations during postprandial periods exhibited a more 
specific triggering effect on oxidative stress than chronic sustained hyperglycemia 
in type 2 diabetic patients (13). However, no relationship was seen between high 
glucose variability and elevated levels of oxidative stress in patients with type 1 
diabetes, although these patients had higher urinary levels of oxidative stress than 
healthy controls (14). Markers of oxidative stress will be measured in future studies 
to determine the degree of oxidative stress and to study its relationship with skin AF, 
reflecting the accumulation of AGEs, and glycemic variability.
The relatively small numbers of total collected samples of HbA1c per patient (due 
to the short follow-up period) and the overall good glycemic control in our study 
population are two other limitations of our study; the latter could be considered 
as a limitation in assessing the rate of AGE accumulation. We cannot exclude that 
extending the range of glycemic control could have resulted in a stronger contribution 
of the HbA1c parameters to skin AF. Perhaps a stronger relationship would also have 
been found in poorly controlled subjects studied over a longer time period.
This study confirmed that the level of skin AF is partly determined by glycemic 
control defined as different assessments of HbA1c. Information about skin AGE 
levels could be of more important value than HbA1c levels for the development of 
diabetic complications, which could make the noninvasive AFR to a practical adjuvant 
in clinical practice. Follow-up studies have already shown the usefulness of skin AF as 
a new marker in predicting diabetic complications which turned out to be a stronger 
predictor than HbA1c. This was found for microvascular complications as well as for 
macrovascular morbidity and mortality (4,5). The mainstay of diabetes management 
is the prevention of chronic complications, especially cardiovascular disease. The 
presence of a considerable number of patients with micro- and macrovascular 
disease in our well-controlled study population at baseline supports the consensus 
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considered as a substitute for the use of skin AF, reflecting the accumulation of AGEs 
with its vascular damaging effects.
Conclusions
In conclusion, the present type 2 diabetes study showed glycemic control, measured 
by different assessments of HbA1c, as a small contributor to AGE accumulation 
expressed as skin AF. This poor relationship between HbA1c and skin AF in this group 
of type 2 diabetes mellitus patients is in agreement with the results of the DCCT in 
T1DM patients. Skin AGE levels could reflect the gravity of vascular damage even 
better than glycemic control by HbA1c. The finding also suggests other mechanisms 
for increased AGE accumulation, such as oxidative stress.
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CHAPTER 4
SERUM PEROXIREDOXIN 4 AND MORTALITY IN PATIENTS 
WITH TYPE 2 DIABETES (ZODIAC-28) 
Gerrits EG, Alkhalaf A, Landman GWD, Van Hateren KJJ, Groenier KH, Struck J, 







































Background Oxidative stress plays an underlying pathophysiologic role in the 
development of diabetes complications. The aim of this study was to investigate 
peroxiredoxin 4 (Prx4), a proposed novel biomarker of oxidative stress, and its 
association with and capability as a biomarker in predicting mortality in patients with 
type 2 diabetes mellitus (T2DM).
Methods and results Prx4 was assessed in baseline serum samples of 1161 well-
controlled T2DM patients (mean age 67). After a median follow-up period of 5.8 years, 
327 (28%) patients died; 137 cardiovascular deaths (42%). Increased levels of Prx4 
were associated with higher rates of cardiovascular and all-cause mortality. The Cox 
proportional hazard models added the following variables: Prx4 (model 1); age and 
gender (model 2), and BMI, serum creatinine, smoking, diabetes duration, systolic 
blood pressure, cholesterol-HDL ratio, history of macrovascular complications, and 
albuminuria (model 3) as additional potential confounders. Hazard ratios (95% 
confidence interval) for cardiovascular mortality were 1.93 (1.57 – 2.38), 1.75 (1.39 – 
2.20), and 1.63 (1.28 – 2.09) for models 1, 2 and 3, respectively. Hazard ratios for all-
cause mortality were 1.73 (1.50 – 1.99), 1.50 (1.29 – 1.75), and 1.44 (1.23 – 1.67) for 
models 1, 2 and 3, respectively. Addition of Prx4 to a model containing the traditional 
risk factors results in improved prediction of cardiovascular and all-cause mortality. 
Conclusions Higher levels of serum Prx4 are independently associated with an 
increased risk of cardiovascular and all-cause mortality in T2DM and it may have the 
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Introduction
Hyperglycemia and lifestyle factors are key factors in the development of diabetes-
related morbidity and mortality (1-5). The hyperglycemic state is associated with 
higher levels of oxidative stress through the formation of excessive reactive oxygen 
species, which in turn activate the inflammatory cascade (6,7). This process is 
thought to play an important underlying pathophysiologic role in the development 
of diabetes complications, both microvascular and cardiovascular (8).
All aerobic organisms have a number of antioxidant proteins as a protection mechanism 
against oxidative stress. The antioxidant defense system comprises enzymatic and non-
enzymatic systems, that can scavenge oxygen radicals, repair and remove damaged 
intracellular components. Peroxiredoxin enzymes are thiol-dependent peroxidases 
and part of a family of proteins present in aerobic organisms, responsible for the 
degradation of endogenously generated peroxides (9-11). These peroxiredoxin family 
members are distributed in the cytosol, mitochondria, peroxisomes and in plasma, 
which are all potential sites of free oxygen radical production (9). Overexpression or 
upregulation of peroxiredoxins has been found to be associated with higher levels of 
oxidative stress, which suggests a secondary respons of peroxiredoxins to oxidative 
stress (9,12-14). Six isoforms of peroxiredoxins have been described in mammals and 
peroxiredoxin 4 (Prx4) is the only isoform detectable in serum, because it is secreted 
by the endoplasmic reticulum of endothelial cells (15). Animal models of diabetes 
mellitus have shown changes of expression or oxidation state of Prx4 in pancreatic 
islet cells (14,16-18). No serum levels of Prx4 have been measured before in animal 
models neither in human with type 2 diabetes mellitus (T2DM). Serum levels of Prx4 
have been proposed as a biomarker of oxidative stress in patients with rheumatoid 
arthritis and sepsis (19-21). The aim of this study was to prospectively investigate 
whether Prx4 is independently associated with cardiovascular and all-cause mortality 







































Study group and design
The included patients in our study are type 2 diabetic patients participating in a 
shared care project of the Zwolle Outpatient Diabetes project Integrating Available 
Care (ZODIAC) Study. This project started in 1998 in Zwolle, The Netherlands and is 
still ongoing. In short, the objective of the ZODIAC Study was to investigate the effects 
of a shared-care project for type 2 diabetic patients. Sixty-one general practitioners 
participated. The ZODIAC Study was approved by the local medical ethics committee 
and all patients gave their informed consent (22). The present study incorporates 
two cohorts from the ZODIAC Study: one cohort started at the beginning in 1998 
and the other in 2001. The latter was formed in order to investigate the predictive 
capability of skin autofluorescence as a marker of accumulation of advanced 
glycation end products for diabetes-related complications and mortality. This study 
has been described in detail before (23). The first cohort contained 1143 patients and 
the second cohort included 973 patients. There were 427 patients present in both 
cohorts, leaving a combined cohort of 1689 unique patients. 
Data collection
Clinical data were obtained at the time of inclusion in the ZODIAC Study, which 
consisted of a complete medical history including macrovascular complications, 
medication use, diabetes duration and smoking history. Patients were considered 
to have macrovascular complications when they had a history of angina pectoris, 
myocardial infarction, percutaneous transluminal coronary angioplasty, coronary 
artery bypass grafting, stroke or transient ischemic attack. Laboratory and physical 
assessment data, such as glycated hemoglobin (HbA1c), non-fasting lipid profile, 
serum creatinine, albuminuria (albumin-to-creatinine ratio), body mass index (BMI), 
and blood pressure were collected annually. Blood pressure was measured twice with 
a Welch Allyn Sphygmomanometer in the supine position after at least five minutes 
of rest. For each visit the mean blood pressure of two recordings was calculated. 
Of the 1689 included patients, 1374 samples were eligible for further analyses to 
measure Prx4. Complete information on Prx4 and potential confounders in this 
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Serum Peroxiredoxin 4
Prx4 levels were measured in serum samples collected at baseline and stored at 
-80°C until analysis in 2010. Because the performance of one freeze-thaw cycle 
has no consequences for assessing Prx4 levels, no influence of frozen storage on 
the assessed levels is to be expected. The validated immunoluminometric sandwich 
assay which measures Prx4 levels uses two monoclonal mouse antibodies both 
directed against amino acids 39 to 51 at the N-terminus of human Prx4, which 
excludes cross-reactivity with other members of the Prx family (19). The assay 
reports Prx4 concentration as arbitrary units per liter (U/L) and the functional assay 
sensitivity (interassay coefficient of variation <20%) is 0.51 arbitrary U/L. The limit of 
quantitation was 0.38 arbitrary U/L.
Clinical endpoints
The clinical endpoints were cardiovascular and all-cause mortality. In 2009, survival 
status and causes of death were obtained from the local hospital information system 
and the general practitioners concerning the ZODIAC cohort of 1998. Survival status 
and causes of death of the ZODIAC cohort of 2001 were obtained in 2005. Causes 
of death were coded according to the International Classification of Diseases, ninth 
revision (ICD-9). 
Statistical analyses
SPSS version 16.0 (SAS Insitute, Cary, NC, USA) and STATA version 11 (StataCorp, 
College Station, Texas USA) were used for statistical analyses. Continuous variables 
are represented as mean (standard deviation - SD) for normally distributed values 
and as median (interquartile range - IQR) for non-normally distributed variables. 
Cox proportional hazard models were used to investigate the association between 
Prx4 and (cardiovascular) mortality. The selected variables with possible confounding 
effects were age, gender, BMI, serum creatinine, smoking, diabetes duration, systolic 
blood pressure, cholesterol-HDL ratio, history of macrovascular complications, and 
albuminuria. Four models were chosen: a crude model including only Prx4 (model 1), 
a model with age and gender as additional confounders (model 2), a fully adjusted 
model (model 3), and finally a model that contained all the selected confounders 





































Prx4 and serum creatinine were logarithmically transformed because of skewed 
distribution of the data. 
The ph-test was used in combination with inspection of the Schoenfeld residuals 
to test the assumption of proportional hazards at baseline. Calibration was 
investigated using the Groennesby and Borgan test, assessing the goodness of fit 
and determining how well the predicted probabilities agree with the observed risk. 
When the average predicted risk matches the proportion that actually develops 
disease within subgroups of a prospective cohort, the model is considered well 
calibrated (24). In case of a significant association between Prx4 and (cardiovascular) 
mortality, the following analyses were performed. Harrell’s C statistic, a rank-based 
measure, was used to compare how well the different models predict mortality 
(25). The higher the value the better the model predicts mortality. Furthermore, the 
integrated discrimination improvement (IDI) was calculated (26). The IDI is designed 
to evaluate the improvement in prediction of novel markers. It can be interpreted 
as the difference between model-based probabilities for events and non events for 
models with and without Prx4. The IDI is a global measure of correct reclassification 
regarding all possible cut-off values. The 95% confidence intervals for Harrell’s C and 
IDI are given in the results.
Results
Baseline characteristics of the 1161 included patients are presented in strata 
according to Prx4 levels (Table 1). Median (interquartile range, IQR) serum level of 
Prx4 was 0.79 (0.53-1.25) arbitrary U/L. Patients with Prx4 above the median were 
older, had a higher BMI, lower eGFR, lower HDL cholesterol levels, higher HbA1c 
levels, higher prevalence of albuminuria and less frequently received lipid-lowering 
drugs, although the percentage of smokers was lower. After a median (IQR) follow-
up of 5.8 (3.1– 10.1) years, 327 (28%) patients had died, of which 137 (42%) were 



































































































































































































































































































































































































































































































































































































































































































































































































































































































The survivors had lower median (IQR) baseline levels of Prx4 compared to the non-
survivors [0.71 (0.48 – 1.05) arbitrary U/L] versus [1.05 (0.65 – 1.59) arbitrary U/L]; 
p<0.001. Increased levels of Prx4 were associated with higher rates of cardiovascular 
and all-cause mortality (Table 2). These associations persisted after adjustment for 
confounders in models 2 and 3. 
Table 2. Hazard ratios for cardiovascular and all-cause mortality of the logarithmically 
transformed Prx4. Comparison of predictive capability of models for mortality risk prediction 
as determined by the Harrell’s C statistic, and the IDI. 
Model 1 Model 2 Model 3 Model 4
Cardiovascular mortality
Hazard ratio [95% CI] 1.93 [1.57 – 2.38] 1.75 [1.39 – 2.20] 1.63 [1.28 – 2.09] n.a.
Harrell’s C [95% CI] 0.65 [0.61 – 0.70] 0.77 [0.73 – 0.81] 0.82 [0.78 – 0.85] 0.81 [0.77 – 0.84]
IDI % [p] n.a 1.97 [1.03 – 2.91] 0.97 [0.16 – 1.77] n.a.
All-cause mortality
Hazard ratio [95% CI] 1.73 [1.50 – 1.99] 1.50 [1.29 – 1.75] 1.44 [1.23 – 1.67] n.a.
Harrell’s C [95% CI] 0.64 [0.61 – 0.67] 0.79 [0.76 – 0.81] 0.81 [0.78 – 0.83] 0.80 [0.77 – 0.82]
IDI % [p] n.a. 2.38 [1.41 – 3.34] 1.63 [0.82 – 2.44] n.a.
Abbreviations: Prx4, peroxiredoxin 4; HR, hazard ratio; CI, confidence interval; IDI, integrated 
discrimination improvement; NA, not applicable. Cox regression models: Model 1: crude 
model with Prx4; Model 2: adjusted for age and gender; Model 3: adjusted for age, gender, 
smoking (dichotomous), body mass index, systolic blood pressure, duration of diabetes, 
serum creatinine level, cholesterol-HDL ratio, macrovascular complications (dichotomous), 
albuminuria (dichotomous); Model 4: all selected confounders without Prx4.
The Harrel’s C values, as presented in Table 2, show that with increasing numbers of 
confounders, the better the model predicted cardiovascular mortality and all-cause 
mortality. However, no differences in the C values were observed between models 
3 (the fully adjusted model) and model 4 (the fully adjusted model without Prx4). 
Inspection of the Schoenfeld residuals and Stata’s ph-test showed no violations of 
the assumption of proportional hazards. The goodness of fit analyses indicated that 
the models for cardiovascular mortality as well as for all-cause mortality were well 
calibrated. 
Furthermore, the IDI was positive in models 2 and 3 for both cardiovascular and all-
cause mortality.
Figures 1 and 2 show the estimated survival curves for cardiovascular and all-cause 
mortality according to patients with serum levels of Prx4 below the median compared 

























































 Prx4 > median
 Prx4 < median
 
Figure 1. shows the estimated survival curves for cardiovascular mortality according to type 
2 diabetes patients with serum levels of Prx4 below the median compared to patients with 
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Figure 2 shows the estimated survival curves for all-cause mortality according to type 2 
diabetes patients with serum levels of Prx4 below the median compared to patients with 






































Our study provides the first evidence that serum Prx4, a free serum antioxidant, 
is independently associated with increased risk for both cardiovascular and all-
cause mortality in patients with T2DM. Prx4 may also have predictive ability and 
could potentially be used as a novel cardiovascular biomarker. When comparing the 
differences in Harrell’s C between the models 2 and 4, adding Prx4 as a risk factor to 
age and gender (model 2) almost has the same predictive value as compared to all 
traditional cardiovascular riskfactors combined (model 3) for cardiovascular as well 
as for all-cause mortality. Although not completely proven, these results might point 
out a role of Prx4 in the prediction of (cardiovascular) mortality in T2DM.
Recently, the predictive capability of Prx4 was established for 30-days mortality in 
patients with nonspecific complaints presenting at the emergency department (27). 
Patients in this study cohort had a median age of 80 years, and Prx4 was not adjusted 
for possible confounders.
Higher circulating Prx4 levels were found in patients with inflammatory conditions 
like rheumatoid arthritis and sepsis, compared to healthy controls (19,21). In 
patients with sepsis the nonsurviving patients had higher Prx4 levels compared to 
the surviving patients and significant positive correlations were found between Prx4 
and markers of infection and inflammation, like procalcitonin (r = 0.61, p < 0.0001), 
C-reactive protein (r = 0.65, p < 0.0001) and interleukin 6 (r = 0.62, p < 0.0001) (20,21). 
Correlations between Prx4 and antioxidative stress markers have also been described 
before, like albumin (r = - 0.54, p < 0.0001) and bilirubin (r = 0.37, p < 0.001) (20). 
Additional information about correlations with other antioxidant markers and with 
oxidative damage markers would be useful to establish the use of Prx4 as a novel 
biomarker of oxidative stress. 
In response to free oxygen radical production in T2DM, secretion of thiol-dependent 
peroxidases will increase to participate in the removal of these reactive oxygen 
species. It is hypothesized that the intracellular removal of hydrogen peroxides 
by Prx4 and secretion of the enzyme is proportionally upregulated in response to 
the surrounding oxidative stress (11,15). Oxidative stress also causes endothelial 
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contributing to even higher levels of serum Prx4. It still has to be investigated if Prx4 is 
actively removing hydrogen peroxides in the circulation. Perhaps, Prx4, being part of 
the antioxidant defense system, can rather be considered as a marker of endothelial 
cell damage and therefore would indirectly be linked to oxidative stress. 
Patients with higher levels of Prx4 in our study revealed several characteristics that 
may have influenced Prx4 or oxidative stress in general. These include older age, 
higher prevalence of albuminuria, higher BMI, lower levels of HDL and less use of 
lipid lowering drugs like statins. However, even after adjustment for most of these 
confounders, the associations between Prx4 and mortality remained significant.
Our study also had a few limitations. Firstly, our analyses were performed in only 
1161 out of the initially 1689 included patients. Secondly, because we only adjusted 
for a single baseline Prx4 value, we were not able to adjust for potential variability 
in Prx4 concentrations. Finally, care must be taken in interpreting the values of the 
IDI since this measure was not developed in the context of censored data. Besides 
this, there is no consensus regarding the interpretation of the magnitude of the IDI.  
Strengths of our study were that it included over 1000 patients with a long follow up 
period and that we were able to include many confounders which were available for 
almost all patients. Another strength is the use of an immunoluminometric assay, 
which is a sensitive method for a reliable quantification of Prx4 in human serum (19).
To conclude, Prx4 is a circulating antioxidant and is independently associated with 
increased risk of cardiovascular and all-cause mortality in T2DM. Future studies are 
needed to answer the question whether Prx4, as a novel biomarker of oxidative 
stress, may be a new valuable cardiovascular predictor useful for risk stratification 
in T2DM.
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CHAPTER 5
LIFE EXPECTANCY IN A LARGE COHORT OF TYPE 2 
DIABETES PATIENTS TREATED IN PRIMARY 
CARE (ZODIAC-10)
Lutgers HL*, Gerrits EG*, Sluiter WJ, Ubink-Veltmaat LJ, Landman GW, Links TP, 
Gans RO, Smit AJ, Bilo HJ. (*both authors contributed equally)






































Background Most longitudinal studies showed increased relative mortality in 
individuals with type 2 diabetes mellitus untill now. As a result of major changes 
in treatment regimes over the past years, with more stringent goals for metabolic 
control and cardiovascular risk management, improvement of life expectancy should 
be expected. In our study, we aimed to assess present-day life expectancy of type 2 
diabetes patients in an ongoing cohort study.
Methodology and Principal Findings We included 973 primary care type 2 diabetes 
patients in a prospective cohort study, who were all participating in a shared care 
project in The Netherlands. Vital status was assessed from May 2001 till May 2007. 
Main outcome measurement was life expectancy assessed by transforming actual 
survival time to standardised survival time allowing adjustment for the baseline 
mortality rate of the general population.
At baseline, mean age was 66 years, mean HbA1c 7.0%. During a median follow-up 
of 5.4 years, 165 patients died (78 from cardiovascular causes), and 17 patients were 
lost to follow-up. There were no differences in life expectancy in subjects with type 2 
diabetes compared to life expectancy in the general population. In multivariate Cox 
regression analyses, concentrating on the endpoints ‘all-cause’ and cardiovascular 
mortality, a history of cardiovascular disease: hazard ratio (HR) 1.71 (95% confidence 
interval (CI) 1.23 – 2.37), and HR 2.59 (95% CI 1.56 – 4.28); and albuminuria: HR 1.72 
(95% CI 1.26 – 2.35), and HR 1.83 (95% CI 1.17 – 2.89), respectively, were significant 
predictors, whereas smoking, HbA1c, systolic blood pressure and diabetes duration 
were not.
Conclusions This study shows a normal life expectancy in a cohort of subjects with 
type 2 diabetes patients in primary care when compared to the general population. 
A history of cardiovascular disease and albuminuria, however, increased the risk of a 
reduction of life expectancy. These results show that, in a shared care environment, 
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Introduction
The incidence and prevalence of diabetes mellitus has risen worldwide during the 
past few decades. Recently published data from the Framingham Heart Study showed 
an absolute increase in the incidence of diabetes of ~ 2.5% yearly during the 1990s 
compared to the 1970s (1). The proportion of cardiovascular disease attributable to 
diabetes mellitus has increased as well (2). Other studies over the last decades of the 
previous century also showed higher mortality rates in diabetes mellitus compared 
to the general population, mostly due to cardiovascular events (3-7). However, 
since the progress in effective pharmaceutical interventions and more stringent 
regimens for the treatment of hyperglycemia, hypertension, dyslipidemia, and other 
cardiovascular risk factors, trends towards a reduction of (cardiovascular) mortality 
rates amongst diabetic patients have been reported (8-12). This improvement of 
survival was hoped to eventually be comparable to the decrease in cardiovascular 
mortality rates in the general population thanks to aggressive management of 
cardiovascular risk factors.
Most published data were extracted from representative national cohorts in North-
America or the United Kingdom. Some reports showed a decline in mortality rates 
amongst diabetic men only, whereas women showed an increase or no change in 
mortality rates at all (4,8,11,12). A recently published Scandinavian study showed a 
substantial decrease in mortality rates from coronary heart disease in all age groups 
irrespective of sex and diabetes status over two consecutive time periods. However, 
the more than twofold higher mortality from coronary heart disease in diabetes 
patients compared to the non-diabetic population remained over time. Still, these 
findings suggested a longer survival in diabetes patients resulting from intensified 
treatment of cardiovascular risk factors (13). 
Our aim was to investigate present-day life expectancy in a type 2 diabetes population 
treated in primary care, with additional support both for patients and health care 









































In 2001, 973 type 2 diabetes patients participated in a cross-sectional study with 
measurements of skin advanced glycation endproduct (AGE) accumulation as 
described previously (14). This study was embedded in a long-term shared care project 
(ZODIAC: Zwolle Outpatient Diabetes project Integrating Available Care) concerning 
a primary care treated population-based sample of type 2 diabetes patients in an 
eastern district of The Netherlands. Figure 1 shows an overview of the enrolment 
of the current study cohort started from the beginning of the ZODIAC. During this 
project, 32 general practitioners (GPs) were supported by hospital diabetes specialist 
nurses and consultant-physicians (15). 
Patients with type 2 




Treated by an internist Treated by a general 
n= 441 practioner (primary care)
n= 1653
Excluded: terminally ill, Invited to participate in a 
dementia shared care project
n= 67 n=1586
Participants of the shared care Refused 
project  in 2000
n= 1441
n= 145
Included in study cohort 
2001 by having 
Excluded in 2001: 
- no skin AGE measurement
a proper skin AGE (logistic reasons, refusal), n= 320
measurement
n=973
-improper skin AGE measurement, n= 148
n = 468
Figure 1. Flowchart of the enrolment of the type 2 diabetes study cohort from 32 general 
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In short, all type 2 diabetes patients were exclusively treated by their GPs and visited 
the diabetes specialist nurses for evaluation of metabolic control and diabetes related 
complications annually. After these evaluations, treatment advice for individual 
patients as well as for benchmarking was given to the GPs by internists in the Isala 
Clinics in Zwolle, the Netherlands. Advices and referrals were based on guidelines of 
the Dutch College of General Practitioners (16).
Patients with a cognitive disability or terminal disease were not included in the ZODIAC 
study because of their inability to undergo educational programs. Furthermore, 
patients who were physically unable to visit the diabetes specialist nurse at the 
outpatient clinic were not enclosed in the present cohort. 
Ethics Statement
This study was approved by the local ethical committee of the Isala Clinics, Zwolle, 
The Netherlands and all patients gave written informed consent.
Description of Procedures 
Methods of clinical data collection and laboratory assessments have been described 
in detail elsewhere (14). Before participation in our study, based on the 1997 ADA 
guidelines and the Dutch primary care standard (16), diagnosis of diabetes mellitus 
was already made in individuals with fasting plasma glucose levels ≥ 7.0 mmol/liter 
and the following definitions representing diabetic complications at baseline were: 
retinopathy, which was defined as the presence of at least background retinopathy 
or a history of laser coagulation for diabetic retinopathy. Albuminuria was defined as 
an albumin-to-creatinine ratio >3.5 mg/mmol for women or >2.5 mg/mmol for men. 
Diminished sensibility at least at one foot was considered as neuropathy, tested with 
a 5.07 Semmes-Weinstein monofilament, applied on three areas of each foot. The 
presence of microvascular disease was defined as meeting the criteria of retinopathy, 
albuminuria, and/or neuropathy. The presence of cardiovascular disease at baseline 
was defined when meeting at least one aspect of cardiovascular disease: ischemic 
heart disease (IHD), International Classification of Diseases ninth revision (ICD-9), 
codes 410-414 and/or a history of coronary artery bypass surgery or percutaneous 





































(CVAs / TIAs) and/or peripheral vascular disease (PVD). PVD was defined as surgical 
intervention, history of claudication and/or absent pulsations of ankle or foot arteries 
(absence of pulsations of the dorsalis pedis arteries bilaterally was not scored as PVD 
when tibial posterior artery pulsations were present). 
Mortality was registered from the date of inclusion until May 2007. Death was 
certified according to the following procedure. In addition to the list of deceased 
patients reported in the files of the scheduled annual follow-up visits, survival status 
of the patients was obtained from the local hospital information system and verified 
with the GPs. Date of death was collected likewise. None of the GPs had involvement 
or interest in study outcome. Causes of death were coded according to ICD – 9 and 
categorised as: neoplasms (140 – 239), diseases of the cardiovascular system (390 
– 459), diseases of the respiratory system (460 – 519), diseases of the digestive 
system (520 – 579), diseases of the genitourinary system (580 – 629), injury and 
poisoning (800 – 999). Sudden death, with symptoms present for less than one hour, 
was encoded in the category of coronary heart disease. For the in-hospital deaths, 
the medical records were retrieved. For the out-of-hospital deceased patients, the 
assigned causes of death by the GPs were obtained from the medical records of the 
GPs. The coded causes of death were combined to all-cause mortality (all codes) and 
cardiovascular mortality (390 – 459 or sudden death).
Statistical Methods
Life expectancy analysis was performed primarily by the use of ‘standardised survival 
time’ (SST), which is a novel approach to survival analysis (17). SST is another 
expression of follow-up time than survival time in years. This method provides survival 
time, which is adjusted for the median residual life span of individuals in the general 
population with the same age and sex. Due to this standardisation of survival time 
there is no influence of the interactions between age and the presence or effects of 
other risk factors due to age. Furthermore, it allows assessment of the effectiveness 
of treatment on regaining a normal residual life span. SST was calculated as the ratio 
between the observed survival time (follow-up time) of an individual and the median 
residual life span of individuals with the same age and sex in the general population 
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gender specific reports provided by the Dutch Central Office of Statistics, which is 
the national Dutch institution of statistics and demographics (18). The SST at baseline 
is defined as 0, and a SST ratio of 1 is defined as follow-up time corresponding with 
the life expectancy of the general population. Direct comparisons between study 
samples and the general population were done by comparing the 95% confidence 
interval (CI) of each median SST with an expected value of 1. The 95% CI of mortality 
at a SST of 0.25 and 0.5 were calculated and compared with the expected mortality 
as calculated for the age and gender matched general population, assuming Poisson 
distribution of the events. Kaplan-Meier curves were constructed for survival and 
for standardised survival. A Cox proportional hazard model to estimate hazard ratios 
(HR) and 95% CI was used in the standard way using survival time in years, and 
additionally by using SST. Methodologically, it is allowed to use SST instead of survival 
time in years in a Cox-regression model, as it is consistent with the preconditions of 
a Cox regression analysis: an increase in mortality and an increase in follow-up time 
have to be present. This new statistical approach underlines the prognostic value 
of the mentioned risk factors, irrespective of age and sex. Eliminating the effects 
of age and sex excludes the influence of disease-specific risk of age and sex in the 
standardised analysis. P values <0.05 were considered to be statistically significant. 
Clinical and laboratory variables with an expected effect on mortality risk were first 
analysed in a univariate analysis, and secondly, in a multivariate model. Detailed 
analyses were performed specifically for two end-points: all-cause mortality and 
cardiovascular mortality. 
Results 
Characteristics of the 973 type 2 diabetes patients at baseline (2001) are shown 
in Table 1. The population had a relatively short median diabetes duration of 4.2 
(interquartile range 1.6 – 8.3) years and on average an acceptable to good glycemic 
control (mean HbA1c 7.0%). Table 1 also shows the baseline characteristics of 
patients when subdivided in survivors (791 patients) and non-survivors. At the end of 





































had died (17%); 17 patients were lost to follow-up. Minimum follow-up duration of 
all survivors was 5.0 years. Ten of the lost to follow-up persons had a last visit to the 
outpatient clinic between baseline and the end of follow-up; this last registered visit 
date was defined as the end of follow-up for these patients. The remaining 7 persons 
lost to follow-up had a mean age of 68 years, were non-smokers, and 2 patients 
had cardiovascular disease at baseline. Their median diabetes duration was 9.7 years 
with a mean HbA1c of 7.5%. 
The proportion of prescribed lipid-lowering drugs, renin-angiotensin system (RAS) 
inhibitors and antiplatelet therapy at baseline, is shown at the end of Table 1. 
At baseline, antiplatelet drugs were significantly more prescribed in the non-survivors 
compared to the survivors. The proportion of cardiovascular deaths in the study 
population (47%) was increased compared to the general population. In 2007, 31% of 
all deaths in the general Dutch population were due to cardiovascular disease, with 
a highest relative incidence of 38% cardiovascular deaths in the population above 85 
years (18).
Figure 2 shows the Kaplan-Meier curve of the cumulative proportion of survivors in 
our type 2 diabetes population against survival time in years. A Kaplan-Meier plot of 
the cumulative proportion of deaths in our study population against standardised 
survival time is shown in Figure 3; the expected mortality for the age- and gender-
matched general population is also shown. The median standardised survival time 
in our study population was 1.00 [95% confidence interval (CI) 0.88 – 1.12] and did 
not differ from the general population. The cumulative proportion of deaths at half 
standardised survival time (SST = 0.50) was 0.20 (95% CI 0.16 – 0.23), which again did 
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Table 1. Baseline characteristics of type 2 diabetes patients: total and subdivided in survivors 
and non-survivors, expressed as mean ± SD or n (%). 
Characteristic Total 






Age in years 66.4 (11.3) 64.8 (11.1) 73.6 (9.4) <0.001
Male gender (%) 47 46.3 50.9 0.278
Smoking (%) 19.3 19.3 20.6 0.71
Body mass index (kg/m2) 29.38 (4.87) 29.5 (4.8) 28.7 (5.1) 0.077
Systolic blood pressure (mmHg) 146.01 (20.15) 145 (20) 149 (20) 0.015
Diastolic blood pressure (mmHg) 81.18 (10.34) 81 (10) 80 (11) 0.046
Diabetes duration (years) a4.16 (1.62-8.31) a3.92 (1.50-8.04) a5.03 (2.40-10.8) 0.002
HbA1c (%) 6.96 (1.3) 6.95 (1.32) 6.998 (1.23) 0.69
Creatinine (µmol/l) 96.0 (19.88) 94.56 (17.6) 103.16 (27.69) <0.001
Creatinine clearance (ml/min) 76.13 (26.91) 78.8 (26.6) 63.22 (24.75) <0.001
Urinary albumin-to-creatinine
ratio (mg/mmol)
a1.49 (0.80-4.17) a1.35 (0.75-3.44) a3.09 (1.23-11.01) 0.001
Total cholesterol (mmol/l) 5.16 (1.01) 5.17 (1.02) 5.08 (1.00) 0.302
Cholesterol-to-HDL ratio 4.34 (1.23) 4.37 (1.21) 4.22 (1.36) 0.171
HDL cholesterol (mmol/l) 1.25 (0.33) 1.24 (0.32) 1.29 (0.35) 0.141
LDL cholesterol (mmol/l) 2.87 (0.93) 2.85 (0.92) 2.92 (0.98) 0.388
Triglycerides (mmol/l) 2.32 (1.36) 2.39 (1.40) 2.03 (1.14) 0.002
Microvascular disease (%) 54.1 50.2 70.9 <0.001
   Retinopathy (%) 19.6 18.5 24.8 0.050
   Microalbuminuria (%) 25.5 21.4 45.5 <0.001
   Neuropathy (%) 29.1 26 40.6 <0.001
Cardiovascular disease (%)  39.5 34.6 63.6 <0.001
   Ischemic heart disease (%) 21.5 19.6 30.3 0.002
   Cerebrovascular disease (%) 7.8 6.4 14.5 <0.001
   Peripheral vascular disease (%) 23.0 18.1 47.3 <0.001
RAS-inhibitorsb (%) 37.2 36.5 39.4 0.489
Lipid-lowering drugsc (%) 29.8 30.7 26.1 0.234
Antiplatelet drugs (%) 24.9 22.1 38.2 <0.001
Diabetes treatment – Diet only (%) 20.2 21.4 16.4
                          Oral medication (%) 64.1 64.3 63
                          Insulin (%) 9.8 8.3 15.8
                          Both (%) 5.9 5.9 4.8
Seven patients were lost to follow-up and did not define the baseline characteristics of the 
survivors/non-survivors. 
aMedian and interquartile range, bAngiotensin-converting enzyme inhibitors and Angiotensin 
II receptor blockers, cLarge majority represented by statins (99%). Reference values of the 
laboratory: HbA1c 4.0-6.0 %, creatinine 70-110 µmol/l, creatinine clearance (Cockcroft-
formula) 80-120 ml/min, urinary albumin-to-creatinine ratio 0-2.5 for men and 0-3.5 for 






























































































































































      

Figure 3. Kaplan-Meier plot of the cumulative proportions of deaths against Standardised 
Survival Time (SST) in the entire type 2 diabetes group. The median SST in type 2 diabetes 
mellitus (T2DM) 1.00 is not different from the general Dutch population 1.00 (Expected); 
the observed mortality (all-cause) at SST 0.25 and 0.50 of 0.09, respectively 0.20 does not 
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Figure 4 shows the mortality rate in type 2 diabetes patients with albuminuria at SST 
0.25 of 0.15 (95% CI 0.10 – 0.19), which was higher than the expected value of 0.076 
(p=0.002). At SST 0.50 mortality rate was 0.26 (95% CI 0.19 – 0.33), which was also 
higher than the expected value of 0.18 (p=0.014). This also proved to be the case for 
type 2 diabetes patients with a history of cardiovascular disease, who had a higher 
mortality at SST 0.25 [0.13 (95% CI 0.096 – 0.17), p<0.001] and at SST 0.50 [0.25 (95% 








































































































































      

Figure 4. Kaplan-Meier plot of the cumulative proportions of deaths in patients with 
albuminuria against Standardised Survival Time. Cumulative proportions of deaths (all causes) 
against Standardised Survival Time (SST) in type 2 diabetes patients with albuminuria (Alb) yes/
no (+/-), compared to the expected deaths of the general population. Differences in mortality 
between the type 2 diabetes-subgroups and the general population are tested at SST= 0.25 
and SST=0.5. Mortality rate at SST 0.25 is 0.15 [95 % confidence interval (CI) 0.10 – 0.19] and 
the expected value is 0.076 (p=0.002). At SST 0.50 mortality rate is 0.26 (95 % CI 0.19 – 0.33), 











































































































































































      

Figure 5. Kaplan-Meier plot of the cumulative proportions of deaths in patients with previous 
cardiovascular disease against Standardised Survival Time. Cumulative proportions of deaths 
(all causes) against Standardised Survival Time (SST) in type 2 diabetes patients with previous 
cardiovascular disease (CVD) yes/no (+/-), compared to the expected deaths of the general 
population. Differences in mortality between the type 2 diabetes-subgroups and the general 
population are tested at SST= 0.25 and SST=0.5. Mortality rate at SST 0.25 is 0.13 (95% CI 0.096 
– 0.17) and an expected value is 0.076, p<0.001. At SST 0.50 mortality rate is 0.25 (95% CI 0.19 
– 0.30) and the expected value is 0.18, p<0.0001.
Table 2 shows the hazard ratios (HRs) and 95% CI of univariate and multivariate Cox-
regression analyses for all-cause mortality. The HRs in the univariate analyses are 
higher for all cardiovascular disease items compared to the method of using SST in 
the model. In the multivariate analysis, predictive factors for all-cause mortality were 
comparable for both methods when age and gender were included in the model of 
the standard method: a history of cardiovascular disease (HR 1.79 and 1.71) and, 
albuminuria (HR 1.79 and 1.72). Univariate analysis of the endpoint: cardiovascular 
mortality (not shown in Table 2) resulted in the same significant predictive factors, 
but with higher HRs. 
Multivariate analysis of cardiovascular mortality resulted in the same significant 
predictive factors with higher HRs (SST) as well: albuminuria 1.83 (95% CI 1.17 – 
2.89); history of cardiovascular disease 2.59 (95% CI 1.56 – 4.28). Smoking, systolic 





















































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   


























































































































































































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   































































































































































































































































































































































































This study shows a normal median overall life expectancy in a defined cohort of 
type 2 diabetes patients treated in a primary care setting, during a follow-up period 
from 2001 till 2007. This finding strongly suggests that current available treatment 
strategies may eventually lead to a life expectancy equal to the general population 
in this subset of type 2 diabetes patients. Secondly, in this type 2 diabetes study 
population, patients with a history of cardiovascular disease and/or the presence of 
albuminuria still had an increased risk to die before their median life expectancy was 
reached. The differences in effects of all items of cardiovascular disease on ‘survival 
in years’ and SST, could be explained by the age correction enclosed in the SST – 
method. As the prevalence of cardiovascular diseases is increasing with increasing 
age, SST does have definite advantages compared to the ‘classical survival time’ in 
identifying premature mortality. 
Finally, we still found an increased proportion of deaths due to cardiovascular disease 
compared to the general population (47% versus 31%). This is in agreement with 
established observations of increased cardiovascular disease in diabetes, and also 
with the fact that the presence of classical cardiovascular risk factors still is most 
intimately related to life expectancy reduction (13,19). 
The United Kingdom Prospective Diabetes Study reported a 5 years reduction of life 
expectancy for males aged 45 to 50 years at diagnosis of diabetes when compared 
to the general United Kingdom population (6). Estimations of reduction of life 
expectancy for patients with diabetes diagnosed at an older age are not presented 
explicitly in this paper, but might be smaller than 5 years, as other studies showed 
that reduction of life expectancy decreases with diagnosis at older age (5,12,20). 
A large study of the non institutionalised United States population, which was 
conducted between 1971 and 1993, showed a median reduced life expectancy of 8 
years for the diabetic population aged 55-64 years, and a 4 years reduction for the 
diabetic population aged 65-74 years (4). However, these studies were all executed 
in a period during which treatment with statins, angiotensin-converting enzyme 
inhibitors and angiotensin-1 receptor blockers, and antiplatelet medication was much 
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women but no excess mortality in men, included exclusively patients diagnosed with 
type 2 diabetes mellitus over the age of 65 (12). Our study is of additional value, as 
we included primary care type 2 diabetes patients of all ages, representing a large 
amount of the type 2 diabetes patients in The Netherlands, where the majority 
of subjects with type 2 diabetes is treated in primary care according to national 
guidelines. Sixty-four percent of our study population was diagnosed with type 2 
diabetes mellitus before the age of 65 years. 
A previous study in the first ZODIAC-cohort (1998) reported an annual mortality rate 
of 4.8% between 1998 and 2000 (the first three years of the shared care project), 
definitely higher than the mortality rate in the present analysis (~3 %), which was 
performed over the subsequent years within this shared care environment (21). This 
difference could be explained by the fact that the earlier analysis was performed 
in a more extended type 2 diabetes cohort, which also included patients who 
were referred to secondary care. It is also possible that the cohort as presented 
in this first analysis had yet to benefit from longer term participation in a shared-
care environment with supportive care and monitoring of implementation of the 
guidelines. 
More than half of our population received either a statin, RAS-inhibitor or aspirin at 
baseline. At follow-up, this proportion had increased to at least 80%. Widespread 
treatment of the traditional cardiovascular risk factors resulted in vastly improved 
blood pressure readings and lipid levels. This could also be the explanation for 
disappearance of systolic blood pressure from the model to predict mortality. Recent 
studies, although maybe underpowered, addressed the importance of statins and 
blood pressure lowering drugs in patients with type 2 diabetes mellitus, showing 
a reduction in cardiovascular events with these lipid-lowering drugs compared to 
placebo (22-24).
HbA1c had also no effect on life expectancy in uni- and multivariate analysis. This 
may possibly be explained by the low number of patients with poor glycemic control 
(only 7% had a HbA1c >9%). Alternatively, other mechanisms could be involved in the 
development of diabetes related complications. E.g., we recently reported increased 
levels of advanced glycation endproducts (AGEs) rather than HbA1c in the same 





































There are some limitations to our study regarding the possible general applicability 
of the results. Diabetic patients who were referred to the secondary care in the past, 
mainly for reasons of poor metabolic control or comorbidity, were not included in 
this study and almost certainly will have a reduced life expectancy. Also, there has 
been a selection bias by excluding diabetic patients with a very short life expectancy 
(terminally ill patients, cognitive disabled people and patients who were unable 
to undergo educational programs), as described in the methods section. Still, the 
selection comprised a considerable subset of the total population known with type 2 
diabetes (see figure 1), and 40% of the included study population were known with 
cardiovascular disease at baseline. 
Despite this apparent selection bias, we still are able to conclude that we defined 
a large subset of patients with a life expectancy comparable to that of the general 
population of the same age and sex. In The Netherlands, the large majority (70 – 
80%) of type 2 diabetes patients is treated in primary care or in a shared-care setting. 
Therefore, this study population could be representative for the majority of type 2 
diabetes patients in The Netherlands, and probably also for a larger part of type 2 
diabetes patients in other countries with structured diabetes care. 
Our choice to compare life expectancy of this type 2 diabetes cohort to the general 
population can be criticised, since the general population also includes people with 
diabetes, cardiovascular disease, cancer, and other life shortening diseases. We 
nevertheless preferred to choose the general population instead of a non-diabetic 
control group, since one of the aims of caregivers in medical practice is to regain a life 
expectancy for their patients equal to the general population when life expectancy is 
reduced due to a specific disease. 
To visualise whether a life expectancy equal to the general population had been 
achieved, we used SST. Traditional survival analysis focuses more on ‘mortality’ 
within a certain follow-up time, but with this more conventional method it is not 
clear whether it is ‘normal mortality’ or ‘excess mortality’. Using SST, the mortality 
rate is adjusted for the median survival of subjects in the general population of the 
same age and sex. In this way, we eliminate the effect of age and sex, by excluding 
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Excess mortality or a reduced life expectancy will be identified more easily in that 
way. We consider the results of this study to be relevant for clinical practice, because 
they offer a hopeful perspective of a definitely improved life expectancy in type 2 
diabetes patients. We suggest that those results are also (partly) due to the fact that 
these patients were and are participating in a care system promoting adherence to 
evidence-based guidelines and to a system emphasizing close cooperation between 
health care providers focusing on this patient group. 
In summary, this study shows a normal life expectancy in a large subset of type 
2 diabetes patients treated in a primary care setting compared to the general 
population. The presence of previous cardiovascular disease and albuminuria, 
however, is still associated with a markedly reduced life expectancy.
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Introduction
Accelerated formation and accumulation of AGEs occur under circumstances of 
hyperglycemic or oxidative stress in age-related and chronic diseases like diabetes 
mellitus, chronic renal failure , neurodegenerative diseases, osteoarthritis, and non-
diabetic atherosclerosis (1 – 5). Accumulation of irreversibly formed and chemically 
stable AGEs occurs on long-lived proteins such as collagen in the skin, but also in 
vascular basement membranes. This affects their structure and function resulting 
in vascular damage. Adequate renal clearance capacity is an important factor in the 
effective removal of AGEs. In renal failure there is a profound decrease in clearance 
of AGE free adducts, which are formed mainly from proteolysis of glycated proteins. 
Plasma levels of these products are up to 40 fold higher in hemodialysis patients 
compared to healthy subjects. Increased levels of AGE free adducts in plasma is 
also a characteristic of acute and chronic renal failure, whereas accumulation of 
AGE residues on plasma proteins appears to be limited to chronic renal failure (6 – 
8). Generally, AGE residues on plasma proteins are not decreased during a dialysis 
session, while AGE free adducts are indeed removed by hemodiafiltration or other 
dialysis procedures (7). Little is known about tissue accumulation of AGEs on long-
lived proteins in patients with chronic renal failure and patients on hemodialysis. 
Furthermore, both uraemic toxicity and some modalities of renal replacement therapy 
contribute to increased oxidative stress, inducing protein modification, which either 
directly or indirectly contribute to the increased formation of AGEs (2,9). Since tissue 
accumulation of AGEs on long-lived proteins is a long-term process, quantitation of 
the collagen-bound AGEs could reflect “metabolic memory” over several years. Up 
till recently, skin biopsies were needed to properly assess the level of tissue AGE 
accumulation; as this is an invasive and time-intensive method, it is not feasible in 
daily practice. 
The autofluorescence reader
The application of a newly developed noninvasive device, the autofluorescence 
reader (AFR), gives the opportunity to measure skin autofluorescence (AF), which 





































The technique has been validated against AGE measurements in skin biopsies from 
the site of the skin AF measurement, taken in patients on hemodialysis, patients 
with diabetes mellitus and healthy controls. Skin AF correlates with skin levels of 
some AGE residues: Nε-carboxymethyl-lysine (CML), r = 0.55 (p < 0.001); pentosidine, 
r = 0.55 (p < 0.001); Nε-carboxyethyl-lysine (CEL), r = 0.47 (p = 0.002) (10,11) . Thus, 
compared to this laborious and time intensive invasive technique and to serum 
or plasma AGE measurements, the AFR allows for a noninvasive and complete 
automated measurement within 30 seconds with immediate presentation of the 
result, which makes this device suitable for clinical application. The AFR illuminates 
the volar side of a skin surface of the arm of ~4 cm2, guarded against surrounding 
light (Figure 1a).















Figure 1a. Autofluorescence reader in a  Figure 1b. Schematic view of the
clinical setting autofluorescence reader 
The principle of skin AF is based on the fluorescent properties of certain AGEs. 
The excitation light source has a peak intensity of ~370 nm, and emission light and 
reflected light from the skin is measured with a spectrometer in the range 300 – 600 
nm (Figure 1b). Skin AF is calculated by dividing the average light intensity of the 
emission spectrum by the average light intensity of the excitation spectrum, and is 
expressed in arbitrary units. Skin reflection is taken into account by using an internal 
reflection standard. Managing the instrument does not require special training or 
skills, and needs no special preparation of the subjects. Reproducibility of the device 
has been tested in different study populations and showed a mean relative error in 
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and per AFR-system did not differ significantly as well (12). An important limitation 
of the original AFR was the inability to measure people with dark skin type, because 
of the high absorption grade of the excitated light. Recent developments of the AFR 
device have reduced this limitation to a more limited range of people with a very 
dark skin type. Other limitations of skin AF measurement: non-fluorescent AGEs are 
not detected – by definition – with skin autofluorescence, while the fluorescence 
of other non-AGE tissue components in the same range of wavelength may act like 
confounders. Not all AGEs show fluorescent characteristics: hydroimidazolones, CML 
and CEL are important AGEs, but not fluorescent. Furthermore, as already mentioned, 
the fluorescence patterns used by the AFR are not specific for fluorescent AGEs only, 
but could also be due to other fluorophores like nicotinamide adenine dinucleotide 
(NADH) and flavin adenine dinucleotide (FAD). There could also be a contribution of 
the fluorescent oxidation adduct N-formyl-kynurenine (13,14). 
In validation studies, skin AF correlated with the specific AGE skin levels of pentosidine, 
CML, and CEL. Both fluorescent and non-fluorescent skin AGE levels correlated with 
each other, as indicated by the correlation between pentosidine and CML (r = 0.46; p 
< 0.001) (10,11). Despite the reasonable correlation between skin AF and skin biopsy 
AGE content, results still have to be interpreted with the mentioned limitations and 
pitfalls in mind, and perhaps more detailed validation of this technique is required.   
Clinical evidence
Skin AF has already been shown to be related to age, smoking, and diabetes 
mellitus. In type 2 diabetes patients, skin AF is related to HbA1c, diabetes duration, 
microalbuminuria and diabetic complications (12,15). Skin AF has also shown its 
predictive value for mortality and the development of microvascular disease in type 
2 diabetes mellitus, as well as for mortality in hemodialysis patients (16 – 19). Cross-
sectional and longitudinal studies, measuring skin AF, are ongoing in other patient 
groups, in order to find out whether skin AF is a predictor for the development of 





































AGEs and renal disease
Besides hyperglycemia and increased oxidative stress, decreases in glomerular 
filtration rate (GFR) appear to be an important determinant contributing to the 
accumulation of AGEs. As already mentioned, a decline in renal function leads to 
elevated serum AGE levels. Such a relationship was confirmed in diabetes mellitus, 
where progressive nephropathy with decreased renal function was associated with 
increased accumulation of AGEs (20). 
Skin AF in renal failure is not only associated with, but also strongly predictive for 
cardiovascular disease, as shown by the independent predictive value of skin AF for 
total and cardiovascular mortality in hemodialysis patients (19). As for cardiovascular 
dysfunction in hemodialysis patients, it has been shown that plasma AGEs were not 
associated with diastolic function, while skin AF was independently associated with 
diastolic function (21). Prevention of the decline in renal function will probably lead 
to a reduced accumulation rate of AGEs, which in turn might contribute to a less dire 
cardiovascular outcome in patients with renal disease. The relative importance of this 
factor compared to other already known risk factors still awaits proper assessment, 
however. 
Conventional methods of renal replacement therapy are only partially effective with 
regard to AGE clearance; the degree of removal is also dependent on the frequency 
and duration of dialysis (22,23). Also, treatment itself may contribute to AGE 
accumulation; oxidative stress is an important factor leading to AGE-formation, and 
some hemodialysis membranes – depending on their degree of biocompatibility – 
will probably contribute to increased AGE-formation (24). On the other hand, new 
technologies concerning certain high flux membranes, vitamin E-coated low-flux 
dialyzers and convective therapies may lead to less oxidative stress and enhanced 
AGE removal in hemodialysis patients (25). Preliminary evidence suggests that 
high-flux hemodialysis, and the use of low glucose dialysates in peritoneal dialysis 
are associated with lower levels of skin AF (Arsov Z et al. and McIntyre N et al, 
unpublished data).
Renal transplantation results in a decrease in AGE accumulation, though AGE levels 
remain well above those of controls. Moreover, the degree of AGE accumulation 
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transplant dysfunction after renal transplantation (26,27). Increased levels of skin AF 
are associated with several risk factors for chronic renal transplant dysfunction and 
cardiovascular disease (28). Unpublished data show an independent predictive value 
of skin AF for the development of chronic transplant dysfunction, which converge 
with the pathophysiological mechanism of oxidative stress and AGE accumulation 
in the outcome of graft loss in renal transplant recipients (29). Therefore, it can 
be hypothesized that preventive therapy with AGE inhibitors might be helpful in 
preserving renal function in these transplant patients. Again it should be stressed, 
that this hypothesis needs confirmation, and the relative importance of these risk 
factors weighed against the impact of other risk factors.
Skin AF and renal function in a screening setting: are skin AF levels directly related to 
the degree of renal failure?
Indeed, skin AF is correlated to the estimated GFR (eGFR) category, calculated with 
the Modification of Diet in Renal Disease (MDRD) – formula (using the re-expressed 
four-variable MDRD) (30), when performing global tests, as shown in the example 
presented below (Table 1; hitherto, unpublished data). The MDRD was used as a 
screening instrument in a large cohort of subjects with type 2 diabetes mellitus (n = 
973), participating in the ZODIAC trial. 
Table 1. skin AF and MDRD. Compare means of skin AF by One Way Anova: MDRD category 
1 versus 2: p=0.39; 1 versus 3 and 4: p<0.001; 2 versus 3 and 4: p<0.001; 3 versus 4: p=0.009. 
MDRD category
(ml/min/1.73m2)




1.        eGFR ≥ 90
2. 60 < eGFR ≤ 90
3. 30 < eGFR ≤ 60













At first sight, such results appear to vindicate the supposed correlation between eGFR 
and skin AF. However, one has to keep in mind in this assessment that the MDRD 
formula has not been sufficiently validated as a screening tool in subjects older than 
70 years old (43% of our study population). Secondly, one should bear in mind, that 





































the factors related to AGE accumulation. For statistical reasons, the eGFR cannot 
be corrected for age to allow a more reliable assessment. Therefore, we divided the 
same cohort into five groups according to age, and dichotomized the results under 
and above the median of eGFR (Table 2). 
Table 2. Skin AF and eGFR in dichotomized age groups (I = mean skin AF in patients below the 






skin AF ± SD
(Arbitrary units)
II Mean 




50 ≤ age < 60
60 ≤ age < 70



























SD, standard deviation; * Compare means of skin AF by One Way Anova.
Figure 2 shows the correlation between skin AF and MDRD for the entire patient 
group. As can be seen, the dichotomized results do not show a definite and consistent 
correlation between AFR readings and eGFR. Furthermore, Figure 2 speaks for itself 
when assessing the relationship between skin AF and eGFR in a large cohort. The 
r-square value of 0.106 (p<0.001) is rather disappointing. These results suggest, that 
skin AF is not a factor which is strongly associated with renal function, at least not in 
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Figure 2. Scatterplot MDRD versus Skin AF
Conclusion
Skin autofluorescence is a new measurement that may have prognostic utility. This 
noninvasive and non-time-consuming method has been studied mainly in end stage 
renal disease and diabetes mellitus, but studies are ongoing in other patient groups 
as well. Based on the published (but still partly incomplete) evidence, skin AF, as 
assessed in different disease states: diabetes mellitus, renal failure, rheumatoid 
arthritis, is related to and predictive of morbidity and mortality. 
The significance of skin AF as a meaningful tool in screening whole populations 
remains to be defined yet. More research is still needed in other patient populations 
in order to further delineate the exact role of both tissue AGEs and skin AF under 
various conditions. More transversal and longitudinal studies need to be done before 
the AFR can be used as a risk assessment tool in individual patient care. However, 
the potential exists. Maybe in the future, when drugs reducing AGE formation, AGE 
breakers, or dialysis modalities reducing AGE formation will become part of the 
therapeutic inventory, skin AF could offer a tool to identify responders to therapy 
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CHAPTER 7
SKIN AUTOFLUORESCENCE AS A MEASURE OF ADVANCED 
GLYCATION ENDPRODUCT DEPOSITION: 
A NOVEL RISK MARKER IN CHRONIC KIDNEY DISEASE
Smit AJ, Gerrits EG






































Purpose of review Skin autofluorescence (SAF) is a new method to noninvasively 
assess accumulation of advanced glycation end products (AGE) in tissue with low 
turnover. Recent progress in the clinical application of SAF as a risk marker for 
diabetic nephropathy as well as cardiovascular disease in nondiabetic end-stage 
kidney disease, less advanced chronic kidney disease, and renal transplant recipients 
is reviewed.
Recent findings Experimental studies highlight the fundamental role of the interaction 
of AGEs with the receptor for AGEs (RAGEs), also called the AGE-RAGE axis, in the 
pathogenesis of vascular and chronic kidney disease. SAF predicts (cardiovascular) 
mortality in renal failure, and also chronic renal tranplant dysfunction. Long-term 
follow-up results from the Diabetes Control and Complications Trial (DCCT) and 
United Kingdom Prospective Diabetes Study (UKPDS) suggest that AGE accumulation 
is a key carrier of metabolic memory and oxidative stress. Short-term intervention 
studies in diabetic nephropathy with thiamine, benfotiamine and angiotensin-
receptor blockers aimed at reducing AGE formation have reported mixed results. 
Summary SAF is a noninvasive marker of AGE accumulation in tissue with low turnover, 
and thereby of metabolic memory and oxidative stress. SAF independently predicts 
cardiovascular and renal risk in diabetes, as well as in chronic kidney disease. Further 
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Introduction
The measurement of skin autofluorescence (SAF) has become a noninvasive method 
of assessing the accumulation of advanced glycation endproducts (AGEs) as a marker 
of the long-term impact of glycemic and oxidative stress in humans. Interest in 
AGEs as a central marker of the so-called metabolic legacy effect has expanded in 
the context of assessing the long-term effects of early intensive glycemic control in 
diabetes as well as the metabolic effects of chronic kidney disease (CKD) and chronic 
renal transplant dysfunction (1,2*). Kern et al. (3*) recently reported data supporting 
earlier observations identifying the predictive value of AGEs and AGE fluorescence in 
diabetic kidney disease in the DCCT-EDIC study (4). The AGE-RAGE axis is important in 
many forms of renal disease and suggests new approaches for intervention (5**,6*). 
Advanced glycation endproducts: formation and effector pathways
AGEs are formed slowly by the Maillard reaction which is dependent on glucose 
levels, but rapid formation of AGEs occurs via another pathway involving reactive 
carbonyl compounds (RCCs) such as (methyl)glyoxal (the so-called dicarbonyl stress) 
during oxidative stress. The glyoxalase system forms a defense mechanism against 
this pathway (7). A third source of AGEs in humans is the intake of exogenous AGEs 
from food and smoking (8). Overall, accumulation of AGEs on proteins with low 
turnover may result from all these three sources: slow glycation, rapid formation via 
RCCs, and exogenously derived AGEs. When proteins are degraded to the so-called 
glycation-free adducts and glycation adduct residues, the former in particular are 
subsequently excreted via the kidney. In the presence of renal failure, this excretion 
mechanism fails or is overloaded, and further accumulation on proteins with low 
turnover may occur. Dicarbonyl stress is also increased in renal failure (9*). 
AGEs are no innocent bystanders, but exert effects via two pathways. Firstly, 
they crosslink proteins, nucleic acids and lipids, resulting in structural changes, 





































oxidative stress, thereby introducing a vicious circle. Secondly, AGEs link to cell 
membrane receptors, the best known of which is the receptor for AGEs (RAGEs). 
This may lead to activation of intracellular pathways [including prolonged activation 
of nuclear factor-kappa B (NF-κB)], and release of cytokines (5**,10*) which may 
induce endothelial dysfunction and other deleterious vascular effects (11).
Development and validation of skin autofluorescence as marker of 
tissue advanced glycation endproduct accumulation
Several groups have developed devices to easily and rapidly measure SAF for the 
assessment of AGE accumulation in a point of care setting. In 1997, Jager first noticed 
increased fluorescence of skin in diabetic patients during noninvasive capillary 
microscopy, especially in those with complications. This led to the development of 
the so-called autofluorescence reader, a prototype of the AGE reader (DiagnOptics 
Technologies, Groningen, The Netherlands), which became commercially available 
in 2006. Initial results in patients with diabetes were reported in 1999 and were 
followed in 2004 by several publications mainly in the field of diabetes and renal 
failure (12-15). The principle of the method used in the AGE reader is shown in Figure 
1. (16,17). 
Clinical use of a second device that also utilises SAF to assess AGEs, the so-called 
SCOUT device (VeraLight, Albuquerque, New Mexico, USA) was first reported in 2007 
(18). The intention of the SCOUT device is to diagnose diabetes. Maynard compared 
SAF with HbA1c and fasting plasma glucose for the detection of diabetes (confirmed 
by glucose tolerance test) in a naive population-derived cohort and found superior 
performance with SAF. No applications in renal failure have been reported so far. 
Recently, Xu (19) reported the development of a SAF device, but no clinical data 
have been provided yet. These three devices, all measuring SAF, are proposed to 
assess accumulation of AGEs in skin tissue. In case of the AGE Reader, validation of 
the level of SAF against specific AGE molecules [pentosidine, carboxymethyllysine 
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failure and healthy controls (12,13). In a combined analysis, 76% of variance in SAF 
level could be explained by the variance in dermal pentosidine levels in skin biopsies. 
The molecular nature of collagen-linked fluorescence in diabetes and end-stage 
kidney disease (ESKD) has been partially characterized by the detection of a major 
fluorophore, LW-1, with a molecular weight of 623 Da (20).















Figure 1a. Diagrammatic presentation of the AGE reader set-up. An ultraviolet-A light source 
with a peak wavelength of 370 nm illuminates a small skin area, the reflected and fluorescent 
light coming back from the skin is detected by a fiber and fed into a spectrometer for further 
analysis.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
this excretion mechanism fails or is overloaded, and
further accumulation on proteins with low turnover
may occur. Dicarbonyl stress is also increased in renal
failure [9].
AGEs are no innocent bystanders but exert effects via
two pathways. First, they crosslink proteins, nucleic acids
and lipids, resulting in structural changes, malfunction,
and reduced breakdown. Mitochondrial glycation may in
turn enhance oxidative stress, thereby introducing a
vicious circle. Second, AGEs bind to cell membrane
receptors, the best known of which is the receptor for
AGEs (RAGEs). This may lead to activation of intra-
cellular pathways [including prolonged activation of
nuclear factor-kappa B (NF-kB)], and release of cyto-
kines [5,10], which may induce endothelial dysfunc-
tion and other deleterious vascular effects [11].
Development and validation of skin
autofluorescence as marker of tissue
advanced glycation endproduct accumulation
Several groups have developed devices to easily and
rapidly measure SAF for the assessment of AGE accumu-
lation in a point of care setting. In 1997, Jager first noticed
increased fluorescence of the skin in diabetic patients
during noninvasive capillary microscopy, especially in
those with complications. This led to development of
the so-called autofluorescence reader, a prototype of the
AGE Reader (Diagnoptics Technologies, Groningen,
TheNetherlands), which became commercially available
in 2006. Initial results in patients with diabetes were
reported in 1999 and were followed in 2004 by several
publications mainly in the field of diabetes and renal
failure [12–15]. The principle of the method used in the
AGE Reader is shown in Fig. 1 [16,17]. Clinical use of a
second device that also utilises SAF to assess AGEs, the
so-called SCOUT device (VeraLight, Albuquerque, NM,
USA) was first reported in 2007 [18]. The intention of the
SCOUT device is to diagnose diabetes. Maynard com-
pared SAFwith HbA1c and fasting plasma glucose for the
detection of diabetes (confirmed by glucose tolerance
test) in a naive population-derived cohort and found
superior performance with SAF. No applications in renal
failure have been reported to date. Recently, Xu et al. [19]
reported the development of a SAF device but no clinical
data have yet been provided. These three devices, all
measuring SAF, are proposed to assess accumulation of
AGEs in skin tissue. In the case of the AGE Reader,
validation of the level of SAF against specific AGE
molecules [pentosidine, carboxymethyllysine (CML)
and carboxyethyllysine] was reported in patients with
diabetes, renal failure and healthy controls [12,13]. In a
combined analysis, 76% of the variance in SAF level
could be explained by the variance in dermal pentosidine
levels in skin biopsies. The molecular nature of collagen-
linked fluorescence in diabetes and end-stage kidney
disease (ESKD) has been partially characterized by the
detection of a major fluorophore, LW-1, with a molecular
weight of 623Da [20].
AGEs are stable endproducts and form irreversible links
in tissues with low turnover. The extent to which proteins
are modified by accumulation of AGEs is an essential
determinant of their functional and structural effects.
Consequences of AGE modification are more important
in tissues with low turnover, such as the dermis and
glomerular and tubular basement membranes, than in
blood or urine. Januszewski et al. [21] showed a strong
correlation between SAF and AGE-related fluorescence
of the eye lens, another tissue in which proteins with low
turnover are present. Examples of how SAF may reflect
functional and structural tissue damage better than
plasma AGE levels are discussed below.
528 Diagnostics and techniques
Figure 1 Diagrammatic presentation of the advanced glycation




















































(a) An ultraviolet A light source with a peak wavelength of 370nm
illuminates a small skin area; the reflected and fluorescent light coming
back from the skin is detected by a fiber and fed into a spectrometer for
further analysis. (b) Examples of the light intensity differences in skin
fluorescence spectra in the 420–600nm range between a patient with
diabetes (upper tracing) and a healthy control (lower tracing). The left
side of the panel shows the peaked-off light intensities of the light source
with a peak wavelength around 370nm. Skin autofluorescence is the
ratio between the light intensities in the 420–600nm range divided by
the light intensity in the 300–420nm range. (a) Reproduced with
permission from [16]. (b) Reproduced with permission from [17].
Figure 1b. Examples of the light intensity differences in skin fluorescence spectra in the 420-
600 nm range between a patient with diabetes and a healthy control. The left side of the panel 
shows the peaked-off light intensities of the light source with a peak wavelength around 370 
nm. Skin AF is the ratio between the light intensities in the 420-600 nm range divided by the 





































AGEs are stable end products and form irreversible links in tissues with low turnover. 
The extent to which proteins are modified by accumulation of AGEs is an essential 
determinant of their functional and structural effects. Consequences of AGE 
modification are more important in tissue with low turnover, such as the dermis and 
glomerular and tubular basement membranes, than in blood or urine. Januszewski 
et al. (21) showed a strong correlation between SAF and AGE-related fluorescence 
of the eye lens, another tissue in which proteins with low turnover are present. 
Examples of how SAF may reflect functional and structural tissue damage better than 
plasma AGE levels are discussed below.
 
Advanced glycation end products and receptor for advanced glycation 
end products in renal disease
Diabetic nephropathy is the classical model for demonstrating the pathogenetic role 
of AGEs and RAGEs. Glomerulosclerosis in diabetic animals is associated with AGE 
deposition in mesangium as well as hyalinized and/or sclerotic lesions. Mesangial cell 
function is also altered after modification of collagen IV by glucose or methylglyoxal 
(22*). Overexpression of RAGEs accelerates the development of glomerulosclerosis 
in mice (23). In RAGE knockout models, and during inhibition of AGE formation, the 
development of diabetic nephropathy, with respect to both micro-albuminuria and 
renal function loss, is prevented (see further below) (24*). 
AGEs also accumulate in nondiabetic uremic patients despite their normal serum 
glucose levels. Among hemodialysis patients, both diabetic patients and nondiabetic 
individuals have high plasma pentosidine and CML levels. Patients with less advanced 
stages of CKD show a relation between AGE levels (CML) and renal function in selected 
groups and in the general population (25). Hou et al. (26) proposed that AGEs and 
RAGEs may contribute to amplification of inflammation in nondiabetic CKD. Plasma 
pentosidine levels and RAGE expression on monocytes strongly increased in parallel 
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In diabetic and nondiabetic patients with ESKD, peritoneal dialysis treatment causes 
low-grade chemical peritonitis due to the limited biocompatibility of peritoneal 
dialysis fluids that contain high glucose concentrations and, therefore, glucose-derived 
products that are precursors of AGEs. Because RAGE is expressed on endothelial 
and mesothelial cells, the receptor may bind AGEs generated endogenously or 
formed during peritoneal dialysis. The binding of AGEs to RAGEs produces a local 
inflammatory reaction, likely as a consequence of vascular cell adhesion molecule-1 
overexpression, leukocyte adhesion, and cytokine release.
The role of RAGEs in the pathogenesis of CKD has been reviewed in detail recently 
(5**) and in the broader context of vascular disease by Yan (10*) from the same 
group. A more critical view on the relevance of RAGEs in the development of ESKD 
has been provided by Thornalley and Rabbani (9*), who question the relevance 
of the experimental studies with often highly glycated AGE-modified proteins for 
development of human renal failure when plasma protein glycation is less marked. 
However, it must be noted that the degree of AGE modification of proteins in 
tissues with low turnover may be considerably higher than in plasma. Thornalley 
and Rabbani draw attention to another potentially relevant function of the RAGE 
receptor: decreased expression of glyoxalase 1, a component of antiglycation defense 
mechanisms in response to S100A12 protein, making the vasculature vulnerable to 
dicarbonyl stress and related AGE formation. 
Skin autofluorescence in diabetic nephropathy, and prediction of 
macrovascular complications
Initial clinical studies were performed in diabetes mellitus, because it is the classic 
example of increased formation and accumulation of AGEs. SAF was indeed found 
to be approximately 30% higher in patients with type 1 or type 2 diabetes mellitus 
compared to age-matched controls. In a large cohort of well controlled primary care 
type 2 diabetes patients, the presence and degree of microvascular and macrovascular 





































reported that SAF is not only associated with diabetic nephropathy, but that it is also 
a predictor of its development.
SAF was also an independent and strong predictor of macrovascular complications 
as well as mortality. Compared to the different variables in the UKPDS risk engine, 
SAF was the best single predictor, after calendar age, of total and cardiovascular 
mortality. SAF also adds predictive value to the UKPDS risk engine, resulting in risk 
reclassification in 25 – 30% of patients (28**). 
The association of SAF with diabetic nephropathy was recently extended to type 1 
diabetes (29). Additionally, Conway et al. (30) showed a strong correlation of SAF, 
as measured with the SCOUT device, with coronary artery calcification in type 1 
diabetes (with a high discriminative ability of SAF to detect CAC scores > 400 (area 
under the curve of receiver operating characteristic curve 85%).
Skin autofluorescence in renal disease
High levels of SAF, even substantially higher than in patients with diabetes and 
complications, have been reported in several hemodialysis cohorts (13,31,32). 
Diabetic hemodialysis patients had slightly higher levels than nondiabetic 
hemodialysis patients. McIntyre and Chesterton (33) extended these observations to 
peritoneal dialysis patients and reported similarly increased SAF values. In peritoneal 
dialysis patients, SAF correlated with dialysis vintage and also with previous peritoneal 
dialysis glucose exposure, whereas there was no difference between diabetic and 
nondiabetic peritoneal dialysis patients. During a follow-up period of three years, SAF 
appeared to be a strong predictor of mortality in hemodialysis patients, independent 
of previous cardiovascular disease (13). In a report from the Renal Risk in Derby 
(RRID) primary care cohort, McIntyre reported that SAF was related to estimated 
glomerular filtration rate (eGFR) in CKD stage 3, independent of age, the presence 
of diabetes and smoking [McIntyre, Determinants of skin autofluorescence in CKD 
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also independently associated with a history of cardiovascular diasease. In another 
cohort of type 2 diabetes patients and moderate nephropathy, Gerrits et al. (32) 
found that SAF was correlated with eGFR categories. Chabroux (29) confirmed the 
association of SAF with diabetic nephropathy in type 1 diabetes patients.
In hemodialysis patients, SAF is also related to several markers of cardiovascular 
dysfunction. SAF was independently associated with diastolic left ventricular 
function, whereas plasma AGEs were not (34). Ueno et al. (31) found that SAF is 
strongly and independently associated with pulse wave velocity (PWV) as a marker 
of arterial stiffness in ESKD (but also in controls). Ueno et al. also recently reported 
that in patients with ESKD, both SAF and serum pentosidine correlated with carotid 
intima media thickness (IMT), and that SAF was inversely related to endothelial 
progenitor cell (EPC) levels, whereas such a correlation was not observed with 
serum pentosidine. In multiple regression analysis SAF, but not serum pentosidine 
or IMT, was related to EPC levels (35*). In the RRID cohort, McIntyre found a positive 
and independent correlation between SAF and PWV [McIntyre, Determinants of 
skin autofluorescence in CKD stage 3 patients, Poster F-PO1124, American Society 
of Nephrology, 2009]. Thus, in patients with CKD, SAF allows the identification of 
patients with the most marked cardiovascular dysfunction. 
In hemodialysis patients, a population with a high annual mortality, SAF is an 
independent indicator of those at highest risk. However, the clinical value of this 
information may seem limited in the absence of effective treatments. Conventional 
methods of renal replacement therapy are only partially effective with regard to AGE 
clearance, and the degree of removal is dependent on the frequency as well as the 
duration of dialysis (36). Furthermore, the dialysis procedure itself may contribute to 
AGE accumulation: oxidative stress is an important factor leading to AGE formation, 
and hemodialysis membranes, depending on their degree of biocompatibility, 
probably contribute to increased AGE formation as well. On the other hand, new 
technologies including high-flux membranes, vitamin E-coated low-flux dialyzers and 
convective therapies may provoke less oxidative stress and result in enhanced AGE 
removal in hemodialysis patients (37). Preliminary evidence suggests that high-flux 
hemodialysis and the use of low-glucose dialysate in peritoneal dialysis are associated 





































Peritoneal dialysis solutions with a lower glucose content may also reduce serum 
AGEs as a result of reduced glycemic stress. The use of peritoneal dialysis fluids low 
in glucose degradation products results in prolonged technique survival and (more 
importantly) also significant patient survival (38). Preliminary data show that SAF is 
also lower in peritoneal dialysis patients on low or no glucose- containing dialysate 
(McIntyre N et al., unpublished data). These findings suggest that lower tissue AGE 
accumulation over time could be due to lower serum AGE levels and may reduce 
tissue damage. 
The results of ongoing studies, investigating the independent predictive value of SAF 
for cardiovascular risk and further renal function loss in earlier stages of CKD, are 
awaited to assess its clinical value. 
Our study group has also investigated the reversibility of AGE accumulation in 
renal transplantation. Kidney transplantation represents one of the most effective 
approaches to reduce the markedly increased AGE accumulation in dialysis patients, 
although AGE and SAF levels remain well above those of controls. Moreover, the 
degree of persisting AGE accumulation after renal transplantation might be involved 
in the accelerated development of cardiovascular disease and chronic renal transplant 
dysfunction (39). Increased levels of skin AF are indeed associated with several risk 
factors for chronic renal transplant dysfunction and cardiovascular disease (40). 
Importantly, in a large group of patients with a previous kidney transplantation, SAF 
was found to be a strong predictor of chronic transplant dysfunction and mortality 
in the following five years (2*). This strongly suggests that AGEs play an important 
role in the development of chronic transplant dysfunction and mortality, probably by 
accelerating systemic and renal atherosclerosis. SAF may prove valuable for assessing 
this risk in the post-transplant period.
Interventions to reduce advanced glycation end products and skin 
autofluorescence levels as well as clinical end points in renal disease. 
Several approaches directed at reducing the effects of AGEs have been evaluated 
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down renal function decline. In experimental studies by Tan et al. (24*) in an 
obese diabetic mouse model, suppression of RAGE expression within a RAGE -/- 
genotype, and adminstration of alagebrium, an inhibitor of AGE accumulation, both 
and additively prevented renal damage, whereas feeding a low-AGE diet did not. 
The classic anti-AGE compound, aminoguanidine, an inhibitor of AGE formation, 
reduced microalbuminuria in experimental models, but has not been succesful in 
clinical trials because of side-effects (41). Novel AGE breakers, such as TRC418, have 
shown reduction of albuminuria and renal function loss in diabetic rats and are in 
development in human studies (42). In a merged dataset from two clinical studies, 
pyridoxamine was reported to reduce change from baseline in serum creatinine, 
but not microalbuminuria (43). Further development was, however, halted due to 
side-effects. Furthermore, aggravation of renal damage was found in other animal 
models when pyridoxamine was used in combination with ACE inhibitors. Thornalley 
and coworkers (44) reported a protective effect of thiamine and benfotiamine in 
a rat model of diabetic kidney disease. They also reported a modest reduction of 
microalbuminuria in a small short-term study in type 2 diabetes patients using high-
dose thiamine (45), but Alkhalaf et al. (46) failed to find reduction of microalbuminuria 
or urinary excretion of the tubular damage marker KIM-1 in type 2 diabetes patients. 
Experimental studies using ACE inhibitors or angiotensin-receptor blockers (ARBs) 
to inhibit the renin-angiotensin-aldosterone system (RAAS) have reported reduced 
AGE formation (47). This effect of RAAS inhibition is at least partially modulated by 
the RAGE receptor. Several experimental studies using ARB treatment have shown 
reduction in tubular and glomerular AGE accumulation along with reduction of 
renal function loss, tubular damage parameters and proteinuria (48). In one small 
(n=11 diabetic retinopathy patients) 12-week clinical study, candesartan reduced 
urinary CML excretion, but not albuminuria. No other formal controlled studies of 
ARB treatment and its effect on AGE formation in diabetic nephropathy have been 
performed, but in a recent post-hoc analysis of the Irbesartan Diabetic Nephropathy 
Trial study in patients with type 2 diabetes and nephropathy, irbesartan did not alter 
the increase in pentosidine and CML in serum and gave only minimal reduction in 





































One of the fundamental problems with these intervention studies may be their very 
short time frame: it seems improbable that a 3-month or even a 2-year treatment 
period would result in improvement in a condition associated with the accumulation 
of AGEs in tissues with low turnover, such as the basement membrane of the 
glomeruli or tubules, that may have taken years to provoke microalbuminuria or 
renal function loss. There is an urgent need for long-term studies (>2 years) which are 
aimed at preventing microalbuminuria and renal function loss rather than reversing 
it. In nondiabetic CKD the role of low-AGE diets should also be explored in long-
term studies. Dietary AGEs seem to exert negative effects, especially once urinary 
excretion of AGE-free adducts becomes reduced with loss of glomerular filtration 
capacity (50). Finally, the predictive role of SAF levels for mortality and chronic graft 
dysfunction several years after renal transplantation, supports the concept of limited 
and slow reversibility of AGE-induced damage. 
Conclusion
AGEs play a pivotal role in the development and progression of diabetic nephropathy, 
but also of nondiabetic CKD. SAF has been validated as a simple, noninvasive 
method for assessment of AGE content in tissue with low turnover. SAF as marker 
of AGE accumulation is a strong and independent predictor of nephropathy and also 
cardiovascular complications in diabetes. Similarly, in nondiabetic CKD, SAF is related 
to vascular dysfunction and predicts mortality in ESKD. After renal transplantation, 
SAF is a valuable predictor of chronic transplant dysfunction and mortality. The 
investigation of interventions aimed at reducing AGE accumulation in patients with 
renal damage should move from short-term studies in patients with established renal 
damage to long-term prevention in an early phase of diabetes or CKD.
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INCREASED SKIN AUTOFLUORESCENCE: 
A PRONOUNCED MARKER OF MORTALITY IN 
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Background Accelerated formation and tissue accumulation of advanced glycation 
endproducts (AGEs), reflecting cumulative glycemic and oxidative stress, occurs 
in age-related and chronic diseases like diabetes mellitus (DM) and renal failure, 
and contribute to vascular damage. Skin autofluorescence (AF), a non-invasive 
measurement method, reflects tissue accumulation of AGEs. The aim of our study 
was to determine the predictive value of skin AF on overall and cardiovascular 
mortality in hemodialysis patients. 
Methods Baseline skin AF was measured in 105 patients on hemodialysis, 23 had 
DM. Survival status was assessed after a median follow-up period of 4.9 years 
(interquartile range: 2.3 – 6.9 years). 
Results Multivariate Cox regression analysis showed skin AF [hazard ratio (HR) 1.83; 
95% confidence interval (CI) 1.32 – 2.54], pre-existing cardiovascular disease [HR 
2.77; 95% CI 1.48 – 5.18], renal replacement therapy duration [HR 1.10; 95% CI 1.01 – 
1.19], age [HR 1.03; 95% CI 1.01 – 1.06], serum albumin [HR 0.90; 95% CI 0.85 – 0.95], 
hematocrit [HR 0.92; 95% CI 0.86 – 0.98], phosphorus [HR 2.01; 95% CI 1.15 – 3.49], 
and parathyroid hormone (PTH) [HR 0.99; 95% CI 0.98 – 0.996] to be predictors of 
mortality, whereas DM was not. Pre-existing CVD and serum phosphorus were the 
only predictors of cardiovascular mortality. 
Conclusion Skin AF showed to be an independent predictor of overall mortality in 
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Introduction
Overall and cardiovascular mortality rate is much higher in subjects with end stage 
renal disease compared to the general population (1-4). A contributing factor to the 
development of vascular damage is the formation and accumulation of advanced 
glycation endproducts (AGEs), which progressively occurs in all individuals with 
ageing. Accelerated formation and tissue accumulation of AGEs on proteins with 
slow turnover, occur in patients with chronic diseases like diabetes mellitus (DM), 
chronic renal failure, neurodegenerative diseases, and systemic inflammatory 
diseases. These AGEs are formed non-enzymatically under circumstances of glycemic 
or oxidative stress. Compared to healthy subjects, increased oxidative stress and 
reduced antioxidant levels have been found in patients with chronic kidney disease 
(CKD) or those on hemodialysis. Oxidative stress, which accompanies uremia, 
increases the inflammatory state and promotes the alterations of certain molecules 
such as proteins, lipids, and carbohydrates (5-7). Additionally, the impaired excretion 
of the breakdown products of AGE cross-linked proteins, the so-called AGE free 
peptides and adducts, further contributes to the accumulation of AGEs in patients 
with chronic kidney disease. AGEs formed under pro-inflammatory and pro-oxidative 
circumstances will contribute to endothelial dysfunction, and are associated with the 
occurrence of cardiovascular disease (CVD) (8,9). 
A substudy of the Diabetes Control and Complications Trial (DCCT) showed that 
AGE levels in skin biopsies predicted the risk of development or progression of 
microvascular disease in type 1 DM, an observation which is suggestive for the 
deleterious effects of AGEs on the vascular wall (10). 
Tissue accumulation of AGEs can be assessed in skin biopsies, but this is an invasive 
method. The autofluorescence (AF) reader, a noninvasive device, is based on the 
fluorescence properties of certain AGEs. The degree of skin AF reflects the level of 
tissue accumulation of AGEs reasonably well. This method has been validated against 
specific AGE levels in skin biopsies in patients with diabetes, patients on hemodialysis 
and in healthy control subjects (11,12). Cross-sectional and longitudinal analyses 
have already shown the relationship between skin AF as a marker of tissue AGEs, and 





































analyses also showed the association of skin AF with renal and cardiovascular risk 
factors in stage 3 and pre-dialysis CKD patients (12-18). 
The aim of the present study was to address the predictive value of skin AF on overall 
and cardiovascular mortality in hemodialysis patients.
Subjects and Methods
Study Group
Between August 2003 and February 2004, 105 hemodialysis patients who dialyzed in 
the hemodialysis centre of the Isala Clinics in Zwolle, The Netherlands, were included 
in the study cohort. These hemodialysis patients had a three times weekly scheme 
with variable duration of dialysis, all were using biocompatible low-flux membranes. 
Patients with Fitzpatrick class V-VI skin type were excluded from participation, 
because of the reduced ability of the prototype autofluorescence reader to reliably 
measure autofluorescence in these dark skin types. This inability is due to the high 
absorption of both the excitation and emission light when using an ultraviolet light 
source with a certain peak intensity (19,20).
At the end of follow-up, January 2011, survival status of all patients was assessed. 
Approval by the local ethic committee had been obtained and informed consent was 
given by all of the included patients. 
Data collection and definitions
Clinical data and laboratory results were obtained at the time of the baseline skin 
AF measurement. Laboratory data included serum non-fasting total cholesterol, 
creatinine, urea, albumin, hemoglobin, hematocrit, calcium, phosphorus, parathyroid 
hormone, all measured according to the standard laboratory procedures. Physical 
assessment data included body mass index (BMI) and blood pressure. Blood pressure 
assessment was the average of three measurements obtained after disconnection 
of the hemodialysis session in supine position, using an aneroid device, in the week 
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Diagnosis of DM was confirmed using ADA criteria. The European Dialysis and 
Transplant Association Codes were used to define the primary diagnosis of renal 
failure, subdivided in divisions: primary glomerulonephritis, interstitial nephropathies, 
multisystem diseases, DM and not known/other. Some DM patients needed dialysis 
due to another cause of renal disease than diabetic nephropathy.
CVD was defined as: Ischemic heart disease (International Classification of diseases 
(ICD-9) codes 410 – 414 and/or a history of coronary artery bypass surgery or 
percutaneous coronary intervention), cerebrovascular accidents or peripheral 
vascular disease (clinical history of intermittent claudication, percutaneous 
transluminal angioplasty, bypass surgery and/or limb amputation). The presence of 
macrovascular complications was assigned when meeting at least one of the criteria 
for CVD.
Skin autofluorescence
Skin AF was measured at the lower, non-fistula arm by the AF reader (prototype of 
the current AGE Reader; DiagnOptics BV, Groningen, The Netherlands), a noninvasive 
device which illuminates a skin surface of ~ 4 cm2, with an excitation ultraviolet light 
source with peak intensity at ~370 nm. Emission light and reflected excitation light 
from the skin are measured with a spectrometer in the 300 – 600 nm range. AF was 
computed by dividing the average light intensity of the emission spectrum (420 – 
600 nm) by the average light intensity of the excitation spectrum (300 – 420 nm), 
multiplied by hundred and expressed in arbitrary units (AU). Assessing skin AF is 
not a time-consuming method and the operation of the device requires no special 
training or skills. Reproducibility has been tested before and the interindividual 
measurements and intraindividual seasonal variance showed a mean relative error 
of ~ 5% (21). 
Statistical analyses
Student’s t-test was used to compare groups with respect to quantitative variables, 
and Cox-regression analysis was used to estimate the effect and the 95% confidence 
interval (CI) of each predictor: skin AF, serum albumin, DM, pre-existing CVD, renal 





































phosphorus and parathyroid hormone (PTH) on overall and cardiovascular mortality, 
both in a univariate and in a multivariate model correcting for all other predictors.
Results
Baseline characteristics are shown in Table 1; patients were subdivided in a surviving 
patient group and a nonsurviving patient group. Mean age of all the 105 included 
patients was 65 years, 68% were male, and 93% were Caucasian (7% Asian). Causes 
of end stage renal disease were classified in 9% of all patients as DM, in 31% as 
hypertension or renovascular disease, in 21% as primary glomerular disorders and 
in 39% as having another primary disorder causing end-stage renal disease. There 
were 23 type 2 DM patients (there were no type 1 DM patients in our hemodialysis 
group at that time point) who appeared well controlled with a mean HbA1c ± SD of 
6.8 ± 1.2% (51 ± 13 mmol/mol). Obviously, at baseline, the non-surviving patients 
were older, had a higher percentage of DM and pre-existing CVD, had a higher pulse 
pressure, a lower albumin level and a higher skin AF level. After a median follow-up 
time of 4.9 years (interquartile range: 2.3 – 6.9 years), the overall mortality rate was 
66%, and cardiovascular mortality rate was 32%. Crude mortality rate was higher 
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Table 1. Baseline characteristics of hemodialysis patients (total, surviving patients and 
nonsurviving patients). 








Age (year) 54.5 ± 15.1 70.5 ± 10.9a 65.1 ± 14.6
Gender M/F (%) 58/42 73/27 68/32
Smoking (%) 8 17 14
BMI (kg/m2) 25.5 ± 4.5 24.6 ± 4.5 24.9 ± 4.5
Systolic bloodpressure (mmHg) 140 ± 22 149 ± 25 146 ± 24
Pulse pressure (mmHg) 56 ± 18 70 ± 20a 65 ± 20
Median duration of renal replacement 








 Coronary heart disease (%)
 CVA/TIA (%)













Diabetes mellitus (%) 8 29b 22
Creatinine (µmol/l) 983 ± 208 816 ± 232a 873 ± 237
Urea (mmol/l) 27.6 ± 5.4 26.0 ± 6.9 26.5 ± 6.4
Albumin (g/l) 40 ± 4 37 ± 5c 38 ± 5
Total Cholesterol (mmol/l) 3.9 ± 0.9 3.8 ± 1.0 3.8 ± 0.9
Hemoglobin (mmol/L) 7.9 ± 0.7 7.7 ± 0.9 7.8 ± 0.8
Hematocrit (%) 38.2 ± 3.8 37.8 ± 4.6 38.0 ± 4.3
Calcium (mmol/L) 2.36 ± 0.20 2.34 ± 0.20 2.35 ± 0.20
Phosphorus (mmol/L) 1.68 ± 0.43 1.63 ± 0.58 1.65 ± 0.53
Median parathyroid hormone (pmol/L) 19.7 (4.7 – 60.8) 15.6 (6.9 – 33.6) 16.9 (6.6 – 39.5)
Skin AF (AU) 2.74 ± 0.77 3.37 ± 0.86a 3.16 ± 0.88
Data are mean ± SD, unless otherwise indicated. Abbreviations: BMI, body mass index; CVD, 
cardiovascular disease; CVA/TIA, cerebrovascular accident/transient ischemic attack; AF, 






































Univariate Cox regression analysis showed that pre-existing CVD and skin AF were 
the most predictive markers of overall mortality: HR 3.44 (95% CI 2.07 – 5.74), and 
1.72 (95% CI 1.32 – 2.23). DM status had statistically significant predictive value for 
overall mortality in univariate analysis, but not in multivariate Cox regression analysis 
(Table 2), whereas skin AF, serum albumin, pre-existing CVD, renal replacement 
duration at baseline, age, hematocrit, serum phosphorus and PTH showed significant 
predictive value for overall mortality in the multivariate analysis. Surprisingly, 
median (interquartile range) PTH levels of the survivors were higher than those of 
the nonsurvivors: 19.7 (4.7 – 60.8) pmol/L versus 15.6 (6.9 – 33.6) pmol/L.
Table 2. Predictors of overall mortality by univariate and multivariate Cox-regression analysis.
Variable 
Univariate Multivariate
Hazard Ratio                  p     
(95% CI)
Hazard Ratio                  p
(95% CI)
Skin autofluorescence (AU)
Diabetes mellitus (yes versus no)
Pre-existing CVD (yes versus no)







1.72 (1.32 – 2.23)
1.93 (1.15 – 3.26)
3.44 (2.07 – 5.74)
1.01 (0.95 – 1.08)
1.05 (1.03 – 1.07)
1.02 (1.01 – 1.03)
0.93 (0.89 – 0.97)
0.97 (0.92 – 1.03)
0.85 (0.51 – 1.40)











1.83 (1.32 – 2.54)
1.07 (0.61 – 1.87)
2.77 (1.48 – 5.18)
1.098 (1.01 – 1.19)
1.03 (1.01 – 1.06)
1.01 (0.996 – 1.02)
0.90 (0.85 – 0.95)
0.92 (0.86 – 0.98)
2.01 (1.15 – 3.49)











Abbreviations: AU, arbitrary units; CI, confidence interval; CVD, cardiovascular disease; RRT, 
renal replacement therapy.
None of the variables showed significant predictive value for cardiovascular mortality 
in univariate Cox regression analysis. In multivariate analysis, only pre-existing 
CVD and serum phosphorus showed significant predictive value for cardiovascular 
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During follow-up, 28 patients received a kidney transplant of whom 4 patients (1 
DM, 3 non-DM) had died at the end of follow-up. Performing Cox regression analyses 
in the population after exclusion of the transplanted hemodialysis patients did not 
change the initially identified predictive markers of overall mortality.
Discussion
This study showed that skin AF was significantly higher in the nonsurvivor group 
compared to the survivor group. Baseline skin AF was a predictor of overall mortality 
and showed independent predictive value regarding overall mortality besides the 
well-known risk factors serum albumin, pre-existing CVD, renal replacement therapy 
duration at baseline, age, hematocrit, and serum phosphorus, with only little change 
in hazard ratio compared to the univariate analysis. DM per se, usually an important 
predictor of mortality in hemodialysis, did not independently have predictive power 
regarding mortality in the multivariate analysis, probably due to the small group 
size or to the more pronounced role of the other conventional and nonconventional 
cardiovascular risk factors in hemodialysis patients in general. We confirmed the 
independent predictive value of skin AF for overall mortality in hemodialysis patients 
as previous reported, but now with a slightly longer follow up (12). An explanation for 
the predictive value of skin AF, or AGE fluorescence, could be the intermediate role 
of AGEs in the development of vascular complications in DM, renal failure and CVD. 
Besides decreased clearance of AGEs in patients with renal failure, AGE formation is 
accelerated throughout the years during dialysis, resulting in progressive AGEs cross-
linked to long-lived proteins embedded in tissue which may contribute to endothelial 
dysfunction. Additionally, high oxidative stress levels in patients with end-stage renal 
disease prior to the start of renal replacement therapy could contribute to increased 
AGE levels as well (6,9,22). Recent data showed that high skin AF levels, as reflecting 
AGE accumulation, were found in moderate renal failure as well and were associated 
with renal and cardiovascular risk factors (17). 
In contrast to our findings, previous studies on serum AGEs did not show predictive 





































(23,24). This might be due to AGE accumulation in skin collagen and other long-
lived proteins which are supposed to remain more stable than serum AGE levels 
due to a variable clearance of circulating serum AGEs in patients with chronic kidney 
disease. Circulating serum AGEs apparently do not properly mirror chronic tissue 
AGE accumulation and its ensuing vascular damage on the long term. A recent report 
observed a relationship between diastolic dysfunction and skin AF in hemodialysis 
patients, whereas serum AGEs did not support this concept (25). Another explanation 
for the higher variability of circulating serum AGEs in hemodialysis patients may be 
the use of different dialysis modalities (26-28). 
Both PTH and phosphorus are well-known risk factors for mortality in hemodialysis 
patients. Although the two variables are most probably depending on each other, 
they both have their independent effect on mortality. PTH was negatively associated 
with mortality, with a wide spread of PTH levels in our study group, and with 
surprisingly higher levels of PTH in the survivor group. This paradoxical finding could 
be explained by the fact that part of the patients underwent a parathyroidectomy 
because of tertiary hyperparathyroidism, and lost their ability to produce large 
amounts of PTH, thus masking a possible correlation between severe parathyroid 
dysfunction and increased mortality risk. 
Several factors may play an important role in the pathogenesis of the so-called 
‘chronic kidney disease’-associated wasting. Hypoalbuminemia is just one aspect 
occurring in correlation with those factors and therefore in line with our finding 
of being associated with mortality. Other factors contributing to protein-energy 
wasting in chronic kidney disease include systemic inflammation, changes in 
appetite-controlling hormones from reduced renal clearance, aberrant neuropeptide 
signalling, insulin and insulin-like growth factor resistance, and metabolic acidosis 
(29,30). Consequently, hemodialysis patients are exposed to chronic inflammation, 
which might contribute to or overlap with the deleterious effects of oxidative stress 
in the development of arterial vascular disease. Unfortunately, we did not have 
sufficient data regarding nonconventional cardiovascular markers of oxidative stress 
or inflammation (like hs-CRP and IL-6). 
There are some technical restrictions of the skin AF measurement. The skin AF 
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are nonfluorescent AGEs present in the skin as well that may contribute to the 
overall effects of AGE accumulation. Nevertheless, the predictive value of skin AF is 
repeatedly confirmed in several studies (12-16). Moreover, only patients with skin 
type Fitzpatrick class I-IV could be included in our study at that time, because of the 
limitation of the prototype AF reader to measure in dark skin types. This issue was 
only just solved according to a recent report that skin AF can be measured in dark 
skin types with a newly developed AF reader (31). Other limitations of the study are 
the small sample size and the possible selection bias of the hemodialysis patients 
with DM. Skin AF measurements were performed during hemodialysis, which 
theoretically could temporarily increase skin AF levels in association with higher 
oxidative stress levels induced by dialysis. However, no changes in skin AF before and 
after hemodialysis sessions could be observed, both in high- and low-flux dialysis 
settings (unpublished data: Koetsier M: Optical skin spectra reflect changes in tissue 
after hemodialysis).
In our opinion, our study provides further support for the concept of chronic 
inflammation and oxidative stress, both contributors to accelerated AGE formation 
and accumulation, as important non-conventional cardiovascular risk markers 
of mortality in a hemodialysis population. Measuring skin AF is an elegant and 
noninvasive method for the assessment of the amount of tissue AGEs, contributing 
to identify the mortality risk in hemodialysis patients. 
To summarize, risk factors which activate chronic inflammation and/or oxidative 
stress, contribute to the deleterious effects on the vascular wall in patients on 
hemodialysis. When correcting for other known risk factors, skin AF proved to be 
a pronounced marker of overall mortality in hemodialysis patients, whereas DM, 
another well known risk factor, did not play a role in our study group. 
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Summary
Increased glycemic and oxidative stress play a pivotal role in the pathogenesis of 
vascular damage in high risk groups such as patients with diabetes mellitus (DM) or 
chronic kidney disease, culminating in cardiovascular events, endstage renal disease 
(ESRD) and mortality. 
Chronic exposure to glycemic and oxidative stress translates in often long lasting 
and cumulative changes. Such effects are also described as metabolic memory 
and can be subdivided in short-term and long-term metabolic memory. Short-term 
metabolic, specifically glycemic memory is reflected by e.g. the degree of glycation 
of hemoglobin, measured as HbA1c subfraction representing the degree of glycemic 
control over approximately the last 6 – 8 weeks. Long-term metabolic memory can 
be reflected by the accumulation of advanced glycation endproducts (AGEs) in tissue 
components with slow turnover, such as collagen in the dermis of the skin which has 
a lifetime of about 15 years. The relationship between poor metabolic control and the 
development or progression of diabetic complications has been established in type 
1 DM in the Diabetes Control and Complications Trial (DCCT) and in type 2 DM in the 
United Kingdom Prospective Diabetes Study (UKPDS) during the nineties (1,2). The 
importance of long-term metabolic memory is highlighted in the long-term follow-
up of both landmark trials which also showed an increasing benefit of good glycemic 
control over prolonged time (>10 years), even when the good glycemic control was 
limited to the initial intervention period at the early stage of diabetes (3,4).  
Patients with chronic renal insufficiency have decreased renal clearance capacity of 
serum AGEs and AGE-free adducts, contributing to the accumulation of AGEs. Higher 
levels of AGEs may enhance oxidative stress, introducing a vicious circle. A treatment 
option for end stage renal disease such as hemodialysis, may in itself also induce 
repetitive bouts of oxidative stress and may reduce levels of protective antioxidants. 
All these imbalances of oxidative stress status and increased levels of AGEs will 
contribute to vascular morbidity and mortality in the long term. 
Increased levels of AGEs may represent a useful marker of enhanced glycemic 
and oxidative stress, and moreover long-term metabolic memory. We assessed 






































Part I of this thesis outlines four longitudinal studies performed in a large cohort 
of type 2 DM patients derived from primary care. The included patients were all 
participating in a shared-care project of the Zwolle Outpatient Diabetes project 
Integrating Available Care (ZODIAC) study, which started in 1998 and is still ongoing. 
Baseline skin AF measurements were performed in a cohort of 973 patients in 2001 
– 2002, and a second skin AF measurement was assessed randomly in 452 patients 
from the initial population of 973 patients who were still participating in the shared-
care project in 2004 – 2005. Baseline serum peroxiredoxin 4 (Prx4) levels were 
assessed in 1689 patients originating from two cohorts of the ZODIAC study: one 
cohort started at the beginning in 1998 and the other in 2001.
Chapter 1 outlines the biochemical process responsible for the formation and 
removal of AGEs, oxidative stress and the deleterious effects of AGEs on the vascular 
wall. It also outlines the assessment of AGEs and the development of the AGE reader, 
a non-invasive device which assesses skin AF. 
Chapter 2 provides information about skin AGE levels measured by skin AF. This 
study describes the predictive value of skin AF for the development of microvascular 
complications in a well-controlled type 2 DM population. Skin AF was superior to that 
of many other traditional risk predictors like diabetes duration and HbA1c. Besides the 
independent predictive value for the development of any microvascular complication, 
skin AF also proved to be an independent predictor of the development of neuropathy 
and (micro)albuminuria when assessed in the equation as separate complications. 
These findings were in agreement with the DCCT/EDIC (Epidemiology of Diabetes 
Interventions and Complications) substudy, which also showed the predictive value 
of skin AGE levels for the development or progression of microvascular complications 
in patients with type 1 DM, even after adjustment for HbA1c (1,5). 
In Chapter 3 we investigated whether HbA1c assessments could predict the change 
in skin AGEs during time in type 2 DM. Different integrated assessments of HbA1c 
were used to investigate to what extent they could predict skin AF, as reflecting 
cumulative glycemic stress and therefore tissue AGE accumulation. Hypothetically, 
the accumulation of AGEs in type 2 DM should be predicted by the course of HbA1c 
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The different integrated assessments of HbA1c which were used were: the variance 
of HbA1c, mean HbA1c, maximum HbA1c, and HbA1c at baseline. Adjustments were 
made for variables which could affect the rate of formation and accumulation of AGEs 
during years: baseline skin AF (reflecting baseline AGE accumulation), age, diabetes 
duration, creatinine, and smoking. The results of this study showed that changes in 
skin AF are poorly predicted by the degree of (relatively short-term) glycemic control 
as assessed by HbA1c in a type 2 diabetes group. It is hard to define which marker for 
metabolic control over a certain period is the best predictor of the development of 
chronic diabetic complications. 
In Chapter 4 we prospectively investigated Prx4, a free serum antioxidant, and its 
association with cardiovascular and all-cause mortality in 1161 type 2 DM patients, 
all participating in the earlier mentioned ZODIAC study. For the first time, this study 
showed evidence that Prx4 was independently associated with increased risk for 
both cardiovascular and all-cause mortality in type 2 DM. Therefore, although our 
findings need to be confirmed by others, Prx4 may have the potential to become a 
novel cardiovascular biomarker.
In addition, we were able to show a normal life expectancy of type 2 DM patients 
treated in primary care, when compared to the general population of a Western 
European country (Chapter 5). However, also in this large subgroup of patients, a 
history of cardiovascular disease and albuminuria still remained predictive for a 
reduction of life expectancy. Major changes in treatment regimens over the past 
ten years, with more stringent goals for all aspects of diabetes care, should have 
contributed to a more favourable metabolic memory state and could therefore 
contribute to the improvement of life expectancy in type 2 DM. Data published in 
the last decade already showed a decline in (cardiovascular) mortality rates amongst 
diabetic patients (6-10). 
Part II, among others, describes the accumulation of AGEs, as reflected by skin AF, in 
patients with chronic renal failure and patients on hemodialysis.
Chapter 6 is an editorial comment about AGEs, as assessed by the AF reader, and renal 
function. It outlines the decrease in clearance of serum AGEs and AGE free adducts in 
patients with renal failure, resulting in AGE accumulation (11-13). It also underlines 





































disease or patients on hemodialysis contributing to the formation and accumulation 
of AGEs (14,15). Original data are shown about the possible role of skin AF and 
renal function in a screening setting in 973 patients with type 2 DM participating in 
the ZODIAC study. In contrast to expectations, skin AF did not show a definite and 
consistent correlation with the estimated Glomerular Filtration Rate [calculated with 
the Modification of Diet in Renal Disease (MDRD) formula] in this patient group. To 
explain this, one has to take into account three aspects of the MDRD formula. First, 
the MDRD formula has not been sufficiently validated as a screening tool in subjects 
over 70 years old (43% of our study population); secondly, age plays an important 
role in the MDRD formula, and finally, age in itself is one of the factors related to AGE 
accumulation.
Chapter 7 is an overview of the clinical application of skin AF as a marker of diabetic 
nephropathy as well as cardiovascular disease in nondiabetic ESRD, less advanced 
chronic kidney disease, and renal transplant recipients. This chapter makes a strong 
point for the hypothesis that AGEs play a pivotal role in the development and 
progression of diabetic nephropathy as wel as in nondiabetic chronic kidney disease. 
It also points out the predictive value of skin AF, as a marker of the accumulation of 
AGEs, for the development of diabetic nephropathy, for cardiovascular complications 
in patients with type 2 DM and for mortality in ESRD (16-20). Furthermore, it describes 
a critical approach towards the novel interventions to reduce AGEs. 
In Chapter 8 we investigated and discussed the predictive value of skin AF on overall 
and cardiovascular mortality in hemodialysis patients. Risk factors which activate 
chronic inflammation or induce increased levels of oxidative stress, contribute to an 
accelerated formation and tissue accumulation of AGEs. The accumulation of AGEs, 
as reflected by skin AF, finally leads to deleterious effects on the vascular system in 
hemodialysis patients. Baseline skin AF was significantly higher in the non-survivor 
hemodialysis group compared to the survivor group. Besides the conventional risk 
factors for mortality in hemodialysis patients, skin AF showed independent predictive 
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To summarize, this thesis describes the determinants of cardiovascular risk in two 
high risk patient groups: type 2 DM and patients with chronic kidney disease or 
ESRD. In these high risk patient groups, we showed evidence for skin AF as a marker 
of morbidity and mortality, we studied the association of the potentially novel 
biomarker Prx4 and mortality and we drew attention to predictors of mortality in 
type 2 DM patients compared to the general population. 
Discussion
Skin AF measurement is based on the specific fluorescence characteristics of AGEs, 
reflecting the accumulation of AGEs. Skin AF has been validated against specific 
AGEs in skin biopsies (considered as the gold standard) in patients with diabetes and 
patients on hemodialysis as well as in healthy control subjects (20,21). 
The DCCT skin collagen ancillary study group clearly showed the association of an 
intensive treatment period of hyperglycemia, compared to conventional treatment, 
with lower levels of AGEs in skin collagen. These AGE levels in skin biopsies also 
predicted the risk of development or progression of microvascular disease in type 1 
DM, even after adjustment for HbA1c (1,5). In one of our studies, we found skin AF to 
have predictive value for the development of the composite endpoint microvascular 
disease in type 2 DM, and in particular for neuropathy and microalbuminuria. There 
was no prognostic value of skin AF for retinopathy, when adjusted for other variables. 
The latter negative finding could be due to different reasons. Firstly, diabetes duration 
or the follow-up period to develop retinopathy could have been too short to develop 
retinopathy; maybe retinopathy needs more time to develop. Secondly, a small number 
of patients developed retinopathy compared to the other complications, and finally, 
the pathogenesis of retinopathy may be different compared to that of nephropathy 
and neuropathy (22). Lack of retinopathy progression was also seen in the Medalist 
group (351 type 1 DM patients who have been followed at the Joslin clinic), despite 
extremely long diabetes duration (over 50 years) (23). This study suggests that 
protective factors may play a role in the lack of retinopathy progression, which could 





































effects of hyperglycemia by unknown mechanisms. Secondly, unknown combating 
mechanisms responsible for progression of complications and even facilitation of 
glycemic or metabolic memory could play a role. There also might be endogenous 
protective factors on metabolic memory with certain AGEs playing a specific role, 
which could act as a protective factor in contrast to the deleterious effects of AGEs 
what we have found until now. Hypothetically, the underlying protective mechanisms 
also might have something to do with overexpression or upregulation of certain 
antioxidant system components. Unfortunately, the Medalist study examined serum 
AGE concentrations, whereas we measured skin AF as a better reflection of tissue 
AGE accumulation.
At the moment, the easily applicable and non-invasive technique of skin AF still 
might be the best alternative method to determine the accumulation of tissue AGEs 
in human in a patient-friendly way compared to the gold standard of skin biopsies. 
However, there are some important aspects about this method to consider. First of 
all, not all of the AGEs will be detected by this technique. Nonfluorescent AGEs like 
Nε-carboxymethyllysine (CML) and pyralline will not be measured by the AGE reader. 
Secondly, tissue components that fluoresce in the same range of wavelength might act 
as confounding fluorophores (e.g. NAD(P)H) and thus contribute to a higher variation 
in skin AF level. Furthermore, hemoglobin and melanin are also capable of absorbing 
light in the 330 – 400 nm range, which makes them possible disturbing factors for the 
skin AF measurement. Finally, high oxidative stress levels, irrespective of glycemic 
status, could result in high concentrations of oxidized endproducts. Higher skin AF 
levels have also been found under circumstances of septicemia or acute myocardial 
infarction, both involving high levels of oxidative stress (24,25). Notwithstanding, 
skin AF has shown to be a predictor of microvascular complications, cardiovascular 
events and mortality in diabetes and hemodialysis patients (16,18-20). 
Besides the biomarker skin AF, we also have studied another potential biomarker 
in the same type 2 DM population: Prx4. This study provides indirect evidence 
that higher levels of oxidative stress, as reflected by serum Prx4, an enzyme of the 
antioxidant defense system, increases the cardiovascular risk. Unfortunately, we 
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reflecting oxidative stress, were associated with an increased risk of cardiovascular 
and all-cause mortality. In 2007, Mulder et al. already showed the association of 
skin AF with markers of oxidative stress: serum levels of sRAGE and neopterin in 
predominantly euglycemic patients (26). To strenghten our findings, future research 
to investigate the association of skin AF and Prx4 in our type 2 DM population would 
be an interesting objective of study.
A few more key questions about skin AF remained unanswered, which will be 
discussed in the following paragraph. The recurring question remains whether skin 
AF measurement truly assesses AGEs which are thought to be ultimately responsible 
for the deleterious effects on the vascular wall. If this question can be anwered by 
yes, skin AF could be used as a true surrogate marker of vascular damage. Besides 
the directly damaging effects of AGEs, skin AF could also reflect a certain degree of 
protein modification which additionally is responsible for vascular damage. During 
the last few years, more confirming evidence of the association between skin AF and 
vascular morbidity and mortality in cross-sectional as well as in longitudinal studies 
has been reported. That makes skin AF a more plausible marker of vascular damage, 
which in turn could make skin AF a biomarker for long-term metabolic stress. 
A second issue is whether the excitation of fluorescence indeed represents a true 
estimate of skin AGE accumulation and the AGE accumulation in the walls of all 
arterial vessels larger than capillaries. Skin AF has been validated against skin biopsies 
which correlated well with certain AGEs. To elucidate the second question, autopsy 
studies with the assessment of AGEs in different sizes of arterial vessel walls have to 
be done. 
One also has to pose the question to what extent skin AF measurement is 
representative for the degree of endothelial damage of the vascular wall c.q. 
endothelial dysfunction, by the accumulation of AGEs. Besides skin AF, all endothelial 
function tests are limited in their clinical predictive value, but one could defend 
them by emphasizing their prognostic significance in predicting vascular events. 
Endothelial dysfunction is associated with an increased risk for cardiovascular events. 
Skin AF has shown to be associated with vascular morbidity and mortality in high 





































AF is also elevated in patient groups with inflammatory diseases, such as systemic 
lupus erythematosus, Wegener’s granulomatosis, and rheumatoid arthritis (28-
30). Therefore, these patient groups can be defined as high risk patient groups for 
cardiovascular morbidity and mortality as well. 
Despite all the relationships that were found between skin AF and morbidity and 
mortality, we can not derive valid and reliable conclusions for an individual patient 
level. Moreover, because of the considerable overlap in measurement outcomes 
between subjects with and without incidents during longitudinal follow up, one 
should keep a critical attitude towards the possible predictive value of skin AF in the 
individual patient. In our studies we did not investigate the additional value of skin AF 
in the prediction of mortality compared to the traditional cardiovascular risk factors 
such as systolic bloodpressure, cholesterol and albuminuria. Lutgers, meanwhile, 
studied the additional clinical value of skin AF in the evaluation of risk for fatal and 
non-fatal cardiovascular events and total mortality in type 2 DM. Reclassification of 
cardiovascular risk of type 2 DM patients with a UKPDS risk score < 10% and skin AF 
levels above the median resulted in higher cardiovascular risk ranking. This study was 
limited by a relatively short follow-up period and was too small compared to larger 
studies which are specifically designed to develop risk-prediction models (19). For the 
individual patient, the additional value of skin AF on top of the classical cardiovascular 
risk factors has to be studied more extensively. It would also be interesting to study 
whether or not skin AF could replace the classical cardiovascular risk factors. If so, 
skin AF will get the chance to develop more potential value to become implemented 
in clinical practice.   
To conclude this paragraph, skin AF assessment is an easily applicable tool that 
might be valuable in identifying high risk patients for cardiovascular complications 
or mortality. Clinicians should be aware to translate the skin AF level of an individual 
patient into a prediction on outcome in this specific individual. The clinical use of 
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Future perspectives
At present, skin AF assessed by the current technique, still poses challenges in 
interpretation and applicability on an individual patient level, and therefore is (not 
yet) an instrument which can be advocated for widely clinical use. In general, it 
should be elucidated which AGEs can be identified as being most representative for 
vascular damage. However, the most important AGEs might be different in different 
disease states; for example, in diabetes the compounded effects of oxidation and 
glycation might lead to more and different toxic substances than the effects of uremia 
in advanced renal failure. Chances to ‘one size fits all’ are virtually nonexistent. 
We hypothezise that some individuals have skin AF measurements that might be 
a true representation of the degree of vascular damage by AGEs. Influencing its 
formation and presence might be of value to help preventing complications. Up to 
now, we don’t exactly know yet to what extent therapies used in daily practice to 
influence e.g. glucose control, blood pressure, or lipid profile, influence the degree 
of AGE accumulation, separate from the fact that they possibly decrease the overall 
rate of AGE accumulation. Many of the known treatment regimens to prevent or 
delay the further development of micro- and macrovascular complications exert 
their effects by other (and already reasonably well known) pathways. Therefore, one 
has to criticize newly introduced measurement techniques or novel biomarkers such 
as skin AF and Prx4. Their implemention will only be appropriate if they will lead to a 
consistently different treatment approach. On the one hand, the utility of such novel 
biomarkers might be useful to predict future cardiovascular events, but, on the other 
hand, up to now, the additional gains on top of reducing conventional risk factors 
have been minimal. Nevertheless, it remains important to search for possible new 
biomarkers as adjuncts to conventional risk factors to provide insight into underlying 
mechanisms of diseases and new therapies. Biomarkers such as skin AF and Prx4, can 
become powerful tools when they are clinical applicable and specific enough for an 
individual subject to draw conclusions on longer term prediction of events, and when 
they have impact on drug development with prognostic influence on cardiovascular 
events. The daily clinical use of skin AF will also become more interesting for the 





































AGE crosslink breaker or specific AGE inhibitor. It offers the opportunity to monitor 
these therapies to finally accomplish reduction of cardiovascular events. During 
the past 20 years, research has been done to find efficient AGE breakers without 
toxicity and applicable in human. Still, there are only positive results in experimental 
studies: alagebrium, which inhibits intracellular ROS synthesis, significantly inhibits 
neointimal hyperplasia after carotid injury in diabetic rats. Targeting AGE cross-links 
with alagebrium (ALT-711) reduced ROS which restored relaxation of arteries in a 
rat model of type 2 DM (31,32). No clear clinical beneficial effects of alagebrium 
has been found in human trials yet, but their effects have been studied no longer 
than 36 weeks, which is probably too short. Whenever AGE breakers will become 
available in future, skin AF might be one of the most important tools to properly 
follow up treatment effects of medication administration. Besides the traditional 
cardiovascular risk factors in highly cardiovascular risk patients, follow-up skin AF 
measurements might become an additional clinical parameter of the efficacy of 
the reduction of metabolic burden. If AGE breakers or inhibitors can slow down 
the formation of AGEs, including elimination of possibly harmfull degradation 
compounds, the metabolic burden will decrease in favour of metabolic memory. This 
theory only holds true when skin AF assesses AGEs that are significantly responsible 
for the deleterious effect on the vascular wall and indeed will be degradated by the 
AGE breakers or its accumulation in tissue will be slowed down by AGE inhibitors.  
We have unpublished data concerning follow-up skin AF assessment in 452 type 2 
DM patients (from the already mentioned ZODIAC cohort) after a median follow-up 
period of 3.2 years. These data showed stable follow-up skin AF levels compared 
to baseline skin AF levels in 43% of the study population, and 35% had an increase 
in skin AF levels. Minor positive associations were seen between skin AF level and 
a longer diabetes duration, lower lipid levels, a lower eGFR, not using an ACE-
inhibitor, and/or with previous macrovascular events. These data suggest that in a 
well-controlled type 2 DM population, a higher degree of continuous oxidative stress 
based on various factors may play a role in the progression of AGE accumulation, 
at least when monitored by skin AF. To find more evidence for this hypothesis, 
follow-up assessment of skin AF should be done after a predetermined period for 
at least 5 years, in which AGEs could significantly result in either further damage, or 
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As it stands now, skin AF measurement has definitively shown potential, but 
there are uncertainties left yet. As always can be said after a prolonged period of 
research: more research and specific follow-up studies are warranted to assess the 
very important issue whether skin AF will earn its place in individual health care 
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Inleiding
Hart- en vaatziekten (HVZ) behoren met kanker tot de belangrijkste doodsoorzaken 
in Nederland. In 2010 overleden gemiddeld 58 vrouwen en 51 mannen per dag 
aan HVZ, waarmee het aandeel van HVZ in de totale sterfte 30% voor vrouwen en 
28% voor mannen was. Veelal zijn er risicofactoren aanwezig die bijdragen aan het 
ontstaan van HVZ. Een aantal bekende risicofactoren voor HVZ zijn roken, hoog 
cholesterolgehalte, hoge bloeddruk en hoge bloedsuikers. Het is belangrijk deze 
risicofactoren te onderkennen zodat ze behandeld kunnen worden. Soms blijkt dat 
het zogenoemde HVZ risicoprofiel waarin de bekende risicofactoren meegewogen 
worden, niet afdoende is om een juiste inschatting te maken van het HVZ risico. Het is 
daarom belangrijk onderzoek te blijven doen naar nieuwe methoden en bepalingen 
die kunnen bijdragen aan een betere identificatie van hoog HVZ risicopatiënten 
en op die manier van toegevoegde waarde zijn in de bepaling van het HVZ risico. 
Tevens kan het onderzoek naar deze nieuwe methoden een bijdrage leveren aan het 
begrijpen van onderliggende ontstaansmechanismen van vaatschade wat uiteindelijk 
zal resulteren in HVZ.
Hoge bloedglucosewaarden, ook wel hyperglycemie genoemd, spelen evenals 
oxidatieve stress een belangrijke rol in het ontstaan van vaatschade in 
hoogrisicopatiënten zoals patiënten met diabetes mellitus (DM) of patiënten met 
chronische nierziekten. Dit kan uiteindelijk leiden tot HVZ, met als eindstadium 
nierfalen en overlijden. Oxidatieve stress is een stofwisselingstoestand, 
waarbij meer dan een normale fysiologische hoeveelheid schadelijke reactieve 
zuurstofverbindingen (ROS: ‘reactive oxygen species’) in de cel wordt gevormd 
of aanwezig is. Dit kan ontstaan door bijvoorbeeld roken, bepaalde medicijnen, 
overmatig alcoholgebruik, te lange zonblootstelling, obesitas en hyperglycemie. De 
gevormde reactieve zuurstofverbindingen ontstaan tijdens de verschillende stappen 
in de stofwisseling van de mitochondriën, de energiecentrale van de cel waar 
zuurstof nodig is, en beschadigen alle delen van de cel, inclusief eiwitten, vetten en 
DNA, wat uiteindelijk bijdraagt aan het verouderingsproces. Alle levende wezens die 





































van schadelijke ROS hebben antioxidanten als beschermingsmechanisme, die de 
ROS kunnen wegvangen of de beschadigde celbestanddelen kunnen verwijderen of 
herstellen. 
Chronische blootstelling aan hyperglycemische en oxidatieve stress resulteert 
in cumulatieve en blijvende veranderingen van weefsels, meestal schade. Deze 
veranderingen kunnen op korte termijn opgetreden zijn of op de lange termijn. De 
korte termijn veranderingen worden meer bepaald door het ‘glycemisch’ geheugen, 
welke weergegeven kan worden door het hemoglobine A1c (HbA1c) gehalte, waarbij 
een deel van het hemoglobinegehalte in het bloed versuikerd is. Het HbA1c zegt iets 
over de glucoseregulatie van de voorafgaande 6 tot 8 weken. De veranderingen op 
de lange termijn kunnen worden weergegeven door de stapeling van versuikerde 
eiwitten, de zogenoemde ‘Advanced Glycation Endproducts’ (AGEs). Deze AGEs 
kunnen binden aan weefsels met een trage omzetting zoals bijvoorbeeld collageen, 
een eiwitbestanddeel en onderdeel van het bindweefsel in de huid, dat een omzetting 
heeft van ca. 15 jaar.
In de jaren negentig werd in twee belangrijke studies met diabetes patiënten een 
relatie gevonden tussen een slechte metabole controle en de ontwikkeling of 
progressie van complicaties. 
Van patiënten met een chronische nierziekte weten we dat zij een verminderde 
capaciteit hebben om AGEs en hun afbraakproducten uit het bloed te filteren. 
Hogere concentraties van AGEs in het bloed kunnen een bijdrage leveren aan 
versnelde stapeling van AGEs in de weefsels. AGEs op zichzelf kunnen de mate van 
oxidatieve stress ook verhogen, waarmee er een vicieuze cirkel is geïntroduceerd. 
Wanneer nierpatiënten afhankelijk worden van nierfunctievervangende therapie 
zoals hemodialyse, kan dit ook weer oxidatieve stress uitlokken en hierbij kunnen ook 
nog eens de verdedigingsmechanismen tegen oxidatieve stress, de antioxidanten, 
uitgeput raken.
Bovengenoemde dysbalans betreffende oxidatieve stress status en verhoogde 
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Verhoogde waarden van AGEs zouden een bruikbare bepaling van verhoogde 
glycemische en oxidatieve stress status kunnen weergeven en daarmee de 
weefselveranderingen op de lange termijn goed kunnen weerspiegelen. 
In dit proefschrift wordt een methode beschreven waarbij er door middel van 
een eenvoudige, niet invasieve meting een inschatting gemaakt kan worden 
over de hoeveelheid AGEs in de weefsels. Het meetinstrument, de huid 
autofluorescentiemeter (ook wel AGE reader genoemd), maakt gebruik van de 
fluorescerende eigenschappen van sommige AGEs. De AGE reader is een draagbaar 
apparaat dat met behulp van ultraviolet licht de huid kan laten fluoresceren. Een 
ingebouwde spectrometer analyseert dan de fluorescentie die de huid uitzendt, ook 
wel huid autofluorescentie genoemd. Berekening door een computerprogramma 
levert uiteindelijk een bruikbaar getal. In validatiestudies is reeds aangetoond dat 
huid autofluorescentie een goede maat voor weefsel AGEs is. 
Meerdere studies hebben ondertussen aangetoond dat de gemeten huid 
autofluorescentie bij patiënten met DM en nierinsufficiëntie hoger is dan in een 
controle groep en dat huid autofluorescentie in deze groepen patiënten geassocieerd 
is met HVZ en sterfte.
Doelstellingen en uitkomsten van dit proefschrift
Deel I van dit proefschrift beschrijft 4 studies die gedaan zijn in een grote groep 
type 2 diabetes patiënten uit de eerstelijns gezondheidszorg (huisartsenpraktijken) 
in Zwolle. De patiënten waren allen afkomstig uit het ZODIAC project (Zwolle 
Outpatient Diabetes project Integrating Available Care), wat in 1998 startte en tot 
op heden voortduurt. In het kader van dit ‘transmurale zorg’ project worden deze 
patiënten jaarlijks door een diabetesverpleegkundige gescreend op complicaties, 
waarna de huisarts aan de hand van deze bevindingen een behandeladvies krijgt van 
een internist. Tussen 2001 en 2002 werden er bij 973 type 2 diabetes patiënten huid 
autofluorescentie metingen gedaan. Binnen deze groep werd tussen 2004 en 2005 





































In hoofdstuk 2 werd de mogelijk voorspellende waarde van huid autofluorescentie 
ten aanzien van de ontwikkeling van microvasculaire complicaties onderzocht in de 
hierboven beschreven groep type 2 diabetes patiënten. Deze studie toonde aan dat 
in deze goed gereguleerde type 2 diabetes patiënten huid autofluorescentie een 
belangrijke voorspellende waarde heeft voor de ontwikkeling van microvasculaire 
complicaties in het algemeen vergeleken met de traditionele risicofactoren. 
Daarnaast bleek het ook een onafhankelijke voorspeller voor de ontwikkeling van 
de afzonderlijke microvasculaire complicaties neuropathie (zenuwschade) en 
albuminurie (de aanwezigheid van albumine [= een eiwit] in de urine dat wijst op 
nierschade) te zijn.
Hoofdstuk 3 bestudeerde de voorspellende waarde van glycemische controle voor 
de veranderingen in weefselaccumulatie van AGEs in de hierboven genoemde 
groep diabetes patiënten van de ZODIAC studie, waarin twee huid autofluorescentie 
metingen waren verricht. Hypothetisch gezien zou de stapeling van AGEs in type 2 
diabetes patiënten voorspeld kunnen worden door het HbA1c beloop gedurende een 
bepaalde periode van jaren voorafgaand aan de huid autofluorescentie meting.
Van verschillende soorten HbA1c bepalingen (HbA1c variantie, gemiddelde HbA1c, 
maximum HbA1c en aanvangs-HbA1c) werd onderzocht of ze geassocieerd waren 
met de snelheid van de aanmaak en stapeling van AGEs over een bepaalde tijd. In 
deze studie werd rekening gehouden met variabelen die eveneens van invloed konden 
zijn op de aanmaak en stapeling van AGEs: beginwaarde van huid autofluorescentie, 
leeftijd, diabetesduur, nierfunctie en roken. De resultaten van deze studie toonden 
aan dat veranderingen in huid autofluorescentie niet goed konden worden voorspeld 
door de verschillende soorten HbA1c bepalingen. 
In hoofdstuk 4 werd de antioxidant peroxiredoxine 4 (Prx4) bestudeerd. Zoals 
in het eerste deel van de samenvatting werd uitgelegd, hebben alle aërobe 
organismen beschermingsmechanismen tegen oxidatieve stress: de antioxidanten 
die de schadelijke reactieve zuurstofverbindingen (ROS) kunnen wegvangen of de 
beschadigde celbestanddelen kunnen verwijderen of herstellen. De peroxiredoxines 
zijn enzymen waarvan er 6 isovormen bestaan, en spelen een rol in de afbraak van 
de ROS, waarvan Prx4 de enige isovorm is die in het bloed meetbaar is. Er werd 




































Nederlandse samenvatting (Dutch summary)
10
én sterfte door alle oorzaken in een type 2 DM populatie uit het eerder genoemde 
ZODIAC cohort. Deze studie toonde voor het eerst aan dat Prx4 een voorspeller bleek 
voor zowel sterfte ten gevolge van HVZ als voor sterfte door alle oorzaken. Er werd 
eveneens gesuggereerd dat het een potentieel nieuwe ziekte-indicator voor HVZ zou 
kunnen worden.
De levensverwachting van type 2 diabetes patiënten in de genoemde ZODIAC studie 
werd in hoofdstuk 5 bestudeerd. Dit werd vergeleken met die van de algemene 
Nederlandse bevolking. Er bleek in deze studie sprake te zijn van een normale 
levensverwachting in deze groep type 2 diabetes patiënten ten opzichte van de 
algemene Nederlandse bevolking. Tevens waren zowel een voorgeschiedenis met 
HVZ als albuminurie nog wel een voorspellende waarde voor een verminderde 
levensverwachting, wat we uit andere studies ook weten. Door een goede 
diabeteszorg te leveren en het behalen van de streefwaarden wat betreft o.a. 
glucoseregulatie, bloeddruk en cholesterolprofiel zou er wellicht een gunstiger 
metabool profiel kunnen ontstaan, wat mede zou kunnen bijdragen aan de verbeterde 
levensverwachting over de afgelopen jaren.
Deel II van dit proefschrift omvat een drietal artikelen die betrekking hebben op de 
stapeling van AGEs en huid autofluorescentie in patiënten met chronisch nierfalen en 
hemodialyse patiënten.
Hoofdstuk 6 is een overzichtsartikel over AGEs, huid autofluorescentie en nierfunctie. 
Hierin wordt benadrukt dat patiënten met chronisch nierfalen een verminderde 
nieruitscheiding van AGEs en hun afbraakproducten uit het bloed hebben. Er wordt 
eveneens beschreven dat er meer oxidatieve stress in patiënten met chronisch 
nierfalen en hemodialyse patiënten is, wat op zijn beurt weer een extra aanleiding 
geeft tot vorming en stapeling van AGEs. Daarnaast staan er in hoofdstuk 6 originele 
data vermeld wat betreft huid autofluorescentie in relatie staande tot nierfunctie 
bij de type 2 diabetes patiënten van de in Deel I genoemde ZODIAC studie. In 
tegenstelling tot wat er verwacht werd, bleek huid autofluorescentie in deze groep 
niet een duidelijke correlatie met de nierfunctie te tonen. 
De toepasbaarheid wat betreft de meting van huid autofluorescentie als risicobepaling 





































niet-diabetisch nierfalen, milde nierfunctiestoornissen en niertransplantatie wordt 
besproken in hoofdstuk 7. Hierin wordt genoemd dat AGEs een belangrijke rol spelen 
in zowel de ontwikkeling van diabetische nefropathie als in niet-diabetisch nierfalen. 
In dit artikel wordt eveneens een kritische houding aangenomen ten opzichte van de 
medicamenteuze interventies om de vorming en stapeling van AGEs tegen te gaan. 
Behandeling met deze middelen vindt enkel in studieverband plaats en is tot op 
heden nog niet klinisch toepasbaar.
In hoofdstuk 8 werd de voorspellende waarde van huid autofluorescentie voor 
sterfte ten gevolge van HVZ als voor sterfte door alle oorzaken in een groep van 
105 hemodialysepatiënten onderzocht. Naast de traditionele risicofactoren bij 
hemodialysepatiënten, bleek huid autofluorescentie enkel een voorspeller voor 
sterfte door alle oorzaken te zijn. 
Samenvattend beschrijft dit proefschrift verschillende factoren die de ontwikkeling 
van HVZ risico in patiënten met type 2 DM en patiënten met chronisch nierfalen 
of eindstadium nierfalen mede bepalen. In deze hoogrisicopatiënten hebben we 
aangetoond dat huid autofluorescentie een voorspeller is voor het optreden van 
ziektegerelateerde complicaties en sterfte. Eveneens werd in een groep type 2 
diabetes patiënten de associatie tussen een potentieel nieuwe ziekte-indicator 
Prx4 en sterfte bestudeerd én er was aandacht voor voorspellers voor sterfte en 













































































Het is zover! Mijn boekje is af en dat had ik zonder een heel aantal mensen niet voor 
elkaar gekregen. Graag wil ik daarom iedereen bedanken, die op welke wijze dan 
ook, mij heeft ondersteund dit proefschrift tot een goed einde te brengen. Een aantal 
mensen wil ik graag in het bijzonder noemen.
Allereerst dank ik alle patiënten die aan het onderzoek hebben meegewerkt, want 
zonder hen zou dit proefschrift geen inhoud hebben.
Prof. dr. H.J.G. Bilo, beste Henk, als een vader zorg jij voor je onderzoekers. Inhoudelijk 
van grote waarde en mentaal ondersteunend, een grote inspiratiebron en toch 
zo’n gewoon prettig mens. Samen met je onderzoekskroost bezoek je jaarlijks de 
EASD congressen in mooie Europese steden, waar er samen gepresteerd, gedeeld, 
gelachen en heerlijk gegeten en gedronken wordt. Wat heb ook ik ervan genoten! 
Wetenschappelijk heb je mij naar een hoger niveau getild. Ik kan het niet in woorden 
uitdrukken hoe dankbaar ik je voor alles ben, maar als ik een gouden Olympische 
medaille zou mogen uitreiken, is die voor jou!
Prof. dr. R.O.B. Gans, beste Rijk, als promotor gaf je, zoals je zelf altijd zei, “ongezouten 
kritiek” op mijn stukken. Kritiek krijgen is niet leuk, maar deze werd door mij erg 
gewaardeerd; het was aanvullend en deed mij een dimensie verder kijken. Dank 
daarvoor. In je rol als opleider, heb je mij alle ruimte gegeven een opleidingsweg te 
bewandelen die iets afweek van het gebruikelijke pad. Je hebt mijn buitenlandstage 
mee helpen realiseren door op korte termijn brieven met handtekeningen de deur 
uit te sturen zodat ik voor 8 maanden naar de zon kon. En toen ik het stuur van de 
opleiding even een tel kwijt was, gaf je me snel weer het vertrouwen het stuur zelf 
vast te pakken. Ik dank je voor je vertrouwen in mij.
Dr. A.J. Smit, beste Andries, ik dank je voor je bijdragende kennis en aanvullingen 
op mijn stukken en het onderzoek in het algemeen. Ik bewonder jouw grote 
wetenschappelijke kennisdomein o.a. op het gebied van AGEs, oxidatieve stress 
en huid autofluorescentie. Jij wist altijd de laatst gepubliceerde studies te noemen 





































bijdragende rol. Ik dank je ook voor het feit dat ik momenteel als fellow vasculaire 
geneeskunde bij jou in een prettige leeromgeving ben beland.  
Dr. H.L. Lutgers, beste lieve Helen, wat ben ik blij dat jij op het idee kwam dat ik 
verder kon gaan met jouw onderzoeksproject. En wat ben ik trots dat ik jou als co-
promotor heb, een plek die je zeer verdiend. Jij hebt mij uitstekend begeleid op de 
momenten dat ik inhoudelijk vastliep, uren hebben we aan de telefoon gezeten om 
die ‘SST’ te begrijpen en je bent ook in de laatste fase van de totstandkoming van het 
boekje hulpvaardig geweest. Ik dank je hiervoor én voor het feit dat we vriendinnen 
zijn. Hoewel onze wegen elkaar pas in 2004 kruisten, voelt onze vriendschap voor mij 
alsof we elkaar al vanaf de kleuterschool kennen.
Prof. dr. B.H.R. Wolffenbuttel, Prof. dr. C.J. Tack en Prof. dr. P.M. ter Wee dank ik voor 
het lezen en de goedkeuring van het manuscript.
Susan Logtenberg, Nanno Kleefstra, Alaa Alkhalaf, Gijs Landman, Hans van Hateren, 
Hanneke Hortensius, Hanneke Joosten, Iefke Drion, Angelien Spaans en Peter van 
Dijk, wat heb ik een geweldige tijd met jullie als mede-onderzoekers van het Diabetes 
Kenniscentrum (gehad). Bedankt daarvoor. Susan dank ik speciaal voor de privé 
cursus ‘SPSS-en’. Ik heb een jaar lang gebruik kunnen maken van jouw SPSS kennis 
toen we in 2007 samen de kamer deelden. Nanno, bedankt voor je onuitputtelijke 
nieuwsgierigheid, het doorgraven naar een verklaring en de discussies die daaruit 
voortvloeiden, door jou heb ik echt leren discussiëren. 
Klaas Groenier, hartelijk dank voor je statistische inbreng in een aantal stukken. 
Jij hebt het voor mij onbegrijpelijke deel van mijn onderzoek inzichtelijk weten te 
maken, wat ik aanvankelijk als onmogelijk had beschouwd. Wim Sluiter dank ik voor 
de statistische analyse in het ‘life-expectancy’ stuk. 
Onderstaande mensen wil ik eveneens graag bedanken voor hun directe of 
indirecte bijdrage aan dit proefschrift: Evert van Ballegooie, Bas Houweling, Lielith 






































van Ballegooie, hemodialyse afdeling Isala Klinieken, Reindert Graaff, Thera Links, 
diabetesverpleegkundigen, data-verzamelaars en secretaresses van het MCC-klik, 
Stephan Bakker, Janin Schulte en Joachim Struck. Richard Oei, bedankt voor je hulp als 
ik weer eens bijna mijn laptop uit het raam wilde gooien en voor je rol als postbode. 
Ik dank mijn voorgangers van het ‘huid autofluorescentie onderzoek’: Robbert 
Meerwaldt, Udo Mulder, Jasper Hartog, Helen Lutgers en Marten Koetsier. Wat heb 
ik jullie boekjes vaak in mijn handen gehad! 
De maatschap interne geneeskunde Isala Klinieken te Zwolle dank ik voor de 
goede en fijne opleidingstijd, die ik in een aantal etappes af heb mogen leggen. Jan 
Lambert, mijn rolmodel en fietsmaat, beste Jan, ik ben blij dat je zitting wilt nemen 
in de oppositie. In het bijzonder wil ik mijn opleider van destijds Dr. M.A. Alleman 
bedanken. Beste Maarten, toen ik vanuit de chirurgie bij jou kwam solliciteren als 
AGNIO interne in de Weezenlanden heb je geen moment getwijfeld aan mijn kunnen. 
Jìj hebt je enthousiasme voor het vak op mij overgebracht en hebt mij gevormd tot 
de internist die ik nu ben, waarvoor ik je erg dankbaar ben. Ik dank je voor een 
grenzeloos vertrouwen in mij.
Interne- en Vasculaire stafleden van het UMCG, ik dank jullie voor de prettige sfeer 
op jullie ‘eiland’ van het UMCG waar ik mij thuis voel. Pieter Willem Kamphuisen, 
kersverse hoogleraar, bedankt voor je begeleiding tijdens het laatste deel van mijn 
opleiding tot vasculair geneeskundige en het feit dat je opponent wilt zijn.
Een ander eiland waar ik mij erg thuis voelde was Curaçao. Hier heb ik in 2010 een 
buitenlandstage in het kader van de opleiding met hard werken en veel plezier mogen 
doen. Ik dank alle ‘stafleden’ interne geneeskunde van het St. Elisabeth Hospitaal 
voor de begeleiding én het mogelijk maken van wetenschappelijk onderzoek met 
een aan de huidskleur aangepaste huid autofluorescentiemeter. Ken Berend, ik vind 
het ontzettend leuk dat je deel wilt uitmaken van de oppositie. Ik hoop dat je vragen 






































Zonder sport, ontspanning en vrienden geen promotie! Ik dank daarom mijn 
fietsmaten die al fietsende hun bijdrage hebben geleverd aan dit proefschrift. Wat is 
het fantastisch om samen in de Alpen, Dolomieten of gewoon ‘rondje Lemelerberg’ 
te fietsen met mensen die dezelfde passie hebben. Eva Kouw, lieve Eef, bedankt voor 
je vrouwelijk fietsgezelschap tussen al dat mannengeweld. 
Mijn collegae en borrelmaatjes van de afgelopen jaren dank ik voor hun gezelligheid 
bij etentjes, borrels en theaterbezoeken in Zwolle, Willemstad en Groningen. De 
vriendschappen die hierbij zijn ontstaan, koester ik. 
Beste lieve studievrienden uit Antwerpen: wij kennen elkaar door dik en dun en ik 
hoop dat ons contact altijd zal blijven. Bedankt voor jullie vriendschap en warmte.  
Hanneke Joosten, mede-onderzoeker, collega en vriendin. Lieve Hanneke, fijn dat je 
er altijd voor mij bent als dat nodig is en wat ben ik blij dat jij mijn paranimf bent.
Anja Gerrits, mijn paranimf primus. Wie anders dan jij, zus én wetenschapper, kan 
deze functie het beste vervullen?! Lieve An, wat ben ik een trotse zus, en stiekum een 
beetje jaloers, dat jij een postdoc plek in Boston hebt weten te regelen. Hoewel ik als 
dominante zus je vroeger vaak voor de voeten heb gelopen, hebben we elkaar vanaf 
onze studieperiode gelukkig weer teruggevonden. Bedankt voor je kritische blik op 
en inbreng in dit proefschrift. Met jou aan mijn zijde moet het lukken. 
Mijn familie: Henry & Simone met Silvan en Robine, Anja & Ivar, bedankt voor jullie 
onvoorwaardelijke steun en liefde en daarmee jullie liefdevolle bijdrage aan dit 
proefschrift. Ik dank mijn lieve ouders die er altijd voor mij zijn en voor wie deze ene 
zin van dankbaarheid veel te weinig is. Lieve pap en mam, jullie hebben mij altijd 
vrijgelaten in mijn keuzes zodat ik mijn eigen wil achterna kon gaan. Dat heeft mij tot 
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Voor het bijwonen van 
de openbare verdediging van 
het proefschrift 
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op woensdag 9 januari 2013 om 
11.00 uur precies in het 
Academiegebouw van de 
Rijksuniversiteit Groningen, 
Broerstraat 5 te Groningen
Aansluitend aan de promotie is er 
een receptie in het 
Academiegebouw, 
Broerstraat 5 te Groningen
Vanaf 18.00 uur worden de 
feestelijkheden voortgezet in het 
‘Schimmelpenninck Huys’ 
aan de Oosterstraat 53 
te Groningen
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